US20050119189A1 - Inhibitors of serine proteases, particularly HCV NS3-NS4A protease - Google Patents

Inhibitors of serine proteases, particularly HCV NS3-NS4A protease Download PDF

Info

Publication number
US20050119189A1
US20050119189A1 US10/943,265 US94326504A US2005119189A1 US 20050119189 A1 US20050119189 A1 US 20050119189A1 US 94326504 A US94326504 A US 94326504A US 2005119189 A1 US2005119189 A1 US 2005119189A1
Authority
US
United States
Prior art keywords
aliphatic
independently
ring
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/943,265
Inventor
Kevin Cottrell
Robert Perni
Janos Pitlik
Wayne Schairer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Priority to US10/943,265 priority Critical patent/US20050119189A1/en
Assigned to VERTEX PHARMACEUTICALS INCORPORATED reassignment VERTEX PHARMACEUTICALS INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COTTRELL, KEVIN M., PITLIK, JANOS, PERNI, ROBERT B., SCHAIRER, WAYNE C.
Publication of US20050119189A1 publication Critical patent/US20050119189A1/en
Priority to US12/265,125 priority patent/US8426359B2/en
Priority to US13/851,303 priority patent/US20130316945A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents.
  • the invention further relates to pharmaceutical compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection.
  • the invention also relates to processes for preparing the compounds and methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
  • HCV hepatitis C virus
  • the HCV genome encodes a polyprotein of 3010-3033 amino acids [Q. L. Choo, et. al., “Genetic Organization and Diversity of the Hepatitis C Virus.” Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991); N. Kato et al., “Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis,” Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990); A. Takamizawa et. al., “Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers,” J.
  • the HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication.
  • the NS proteins are derived by proteolytic cleavage of the polyprotein [R. Bartenschlager et. al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions,” J. Virol., 67, pp. 3835-3844 (1993); A. Grakoui et.
  • the HCV NS protein 3 contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decrease viral infectivity [Chambers, T. J. et. al., “Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein”, Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990)].
  • the first 181 amino acids of NS3 have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [C. Lin et al., “Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics”, J. Virol., 68, pp. 8147-8157 (1994)].
  • HCV NS3 serine protease and its associated cofactor, NS4A helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing. HIV protease inhibitors, which inhibit viral protein processing, are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents. Consequently HCV NS3 serine protease is also an attractive target for drug discovery.
  • Such inhibitors would have therapeutic potential as protease inhibitors, particularly as serine protease inhibitors, and more particularly as HCV NS3 protease inhibitors. Specifically, such compounds may be useful as antiviral agents, particularly as anti-HCV agents.
  • the present invention addresses these needs by providing a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
  • the invention also relates to compounds of formula I-1: or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein.
  • compositions that comprise the above compounds and the use thereof.
  • Such compositions may be used to pre-treat invasive devices to be inserted into a patient, to treat biological samples, such as blood, prior to administration to a patient, and for direct administration to a patient.
  • the composition will be used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection.
  • the invention also relates to processes for preparing the compounds of formula I.
  • the present invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein:
  • the present invention also provides a compound of formula I-1: or a pharmaceutically acceptable salt thereof, wherein:
  • aryl as used herein means a monocyclic or bicyclic carbocyclic aromatic ring system. Phenyl is an example of a monocyclic aromatic ring system. Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g., naphthyl, and systems wherein only one of the two rings is aromatic, e.g., tetralin. It is understood that as used herein, the term “(C6-C10)-aryl-” includes any one of a C6, C7, C8, C9, and C10 monocyclic or bicyclic carbocyclic aromatic ring system.
  • bioisostere —CO 2 H as used in herein refers to a chemical moiety which may substitute for a carboxylic acid group in a biologically active molecule. Examples of such groups are disclosed in Christopher A. Lipinski, “Bioisosteres in Drug Design” Annual Reports in Medicinal Chemistry, 21, pp. 286-88 (1986), and in C. W. Thornber, “Isosterism and Molecular Modification in Drug Design” Chemical Society Reviews, pp. 563-580 (1979).
  • Examples of such groups include, but are not limited to, —COCH 2 OH, —CONHOH, SO 2 NHR′, —SO 3 H, —PO(OH)NH 2 , —CONHCN, —OSO 3 H, —CONHSO 2 R′, —PO(OH) 2 , —PO(OH)(OR′), —PO(OH)(R′), —OPO(OH) 2 , —OPO(OH)(OR′), —OPO(OH)(R′), HNPO(OH) 2 , —NHPO(OH) (OR′), —NHPO(OH) (R′)
  • heterocyclyl as used herein means a monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, S, SO, and SO 2 in a chemically stable arrangement.
  • heterocyclyl one or both rings may contain said heteroatom or heteroatom groups.
  • (C5-C10)-heterocyclyl- includes any one of a 5, 6, 7, 8, 9, and 10 atom monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatoms or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
  • heterocyclic rings examples include 3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperid
  • heteroaryl as used herein means a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatoms or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
  • heteroaryl a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatoms or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
  • heteroaryl rings examples include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl
  • aliphatic as used herein means a straight chained or branched alkyl, alkenyl or alkynyl. It is understood that as used herein, the term “(C1-C12)-aliphatic-” includes any one of a C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, and C12 straight or branched alkyl chain of carbon atoms. It is also understood that alkenyl or alkynyl embodiments need at least two carbon atoms in the aliphatic chain.
  • cycloalkyl or cycloalkenyl refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic.
  • Cycloalkenyl rings have one or more units of unsaturation. It is also understood that as used herein, the term “(C3-C10)-cycloalkyl- or -cycloalkenyl-” includes any one of a C3, C4, C5, C6, C7, C8, C9, and C10 monocyclic or fused or bridged bicyclic carbocyclic ring. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, nornbornyl, adamantyl and decalin-yl.
  • the carbon atom designations may have the indicated integer and any intervening integer.
  • the number of carbon atoms in a (C1-C4)-alkyl group is 1, 2, 3, or 4. It should be understood that these designation refer to the total number of atoms in the appropriate group.
  • the total number of carbon atoms and heteroatoms is 3 (as in aziridine), 4, 5, 6 (as in morpholine), 7, 8, 9, or 10.
  • chemically stable arrangement refers to a compound structure that renders the compound sufficiently stable to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive condition, for at least a week.
  • the radical is: wherein:
  • the radical is: wherein:
  • the radical is: wherein:
  • the radical is: wherein:
  • the radical is;
  • the present invention provides a compound of formula IA: wherein:
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is: wherein:
  • the radical is: wherein:
  • R 7 is hydrogen
  • R 7 is hydrogen
  • R 2 is hydrogen
  • the radical is: wherein:
  • the radical is: wherein:
  • the radical is: wherein:
  • the present invention provides a compound of formula IB: wherein:
  • the present invention provides a compound of formula IB-1: wherein:
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is: wherein:
  • the present invention provides a compound of formula IC: wherein:
  • z is 1, Z and Z′ are S, R 9 , R 9′ , R 11 , and R 11′ , are H, R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 7 , R 12 , and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • z is 0, Z and Z′ are S, R 9 , R 9′ , R 11 , and R 11′ are H, R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 7 , R 12 , and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • the present invention provides a compound of formula IC-1: wherein:
  • z is 1, Z and Z′ are S, R 9 , R 9′ , R 11 , and R 11′ are H, R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 7 , R 12 , R 12′ , X, V, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • z is 0, Z and Z′ are S, R 9 , R 9′ , R 11 , and R 11′ are H, R 1 , R 2 , R 3 , R 4 , R 5 , R 5′ , R 7 , R 12 , R 12′ , X, V, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is: wherein:
  • the radical is: wherein:
  • the present invention provides a compound of formula ID: wherein:
  • the present invention provides a compound of formula ID-1: wherein:
  • z is 1.
  • z is 0.
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • z is 0, w is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is:
  • the radical is: wherein the R 10′ group, is independently and optionally substituted with up to 3 substituents independently selected from J.
  • the radical is:
  • the radical is:
  • the radical is:
  • the radical is: wherein up to 5 atoms in R′ are optionally and independently substituted with J.
  • the radical is:
  • the radical is:
  • the present invention provides a compound of formula IE: wherein:
  • the present invention provides a compound of formula IE-1: wherein:
  • z is 1.
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is: wherein;
  • the radical is:
  • the radical is:
  • the radical is:
  • the present invention provides a compound of formula IF: wherein:
  • the present invention provides a compound of formula IF-1: wherein:
  • the present invention provides a compound of formula IF-2: wherein:
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is: wherein;
  • the present invention provides a compound of formula IG: wherein:
  • the present invention provides a compound of formula IG-1: wherein:
  • z is 1.
  • z is 0.
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • z is 0, w is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • the radical is: wherein:
  • the radical is:
  • the present invention provides a compound of formula IH: wherein:
  • the present invention provides a compound of formula 1H-1: wherein:
  • z is 1.
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • W in compounds of formula I or formula I-1 is: wherein in the W, the NR 6 R 6 is selected from —NH—(C1-C6 aliphatic), —NH—(C3-C6 cycloalkyl), —NH—CH(CH 3 )-aryl, or —NH—CH(CH 3 )-heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens.
  • the NR 6 R 6 in the W radical is:
  • the NR 6 R 6 in the W radical is:
  • the NR 6 R 6 is:
  • the NR 6 R 6 in the W radical is:
  • the NR 6 R 6 in the W radical is:
  • the present invention provides a compound of formula IJ: wherein:
  • the present invention provides a compound of formula IJ-1: wherein:
  • z is 1.
  • W in compounds of formula I or formula I-1 is: wherein R 8 is as defined above.
  • each R 8 together with the boron atom is a (C5-C10)-membered heterocyclic ring having no additional heteroatoms other than the boron and the two oxygen atoms.
  • the heterocyclic ring is:
  • W in compounds of formula I or formula I-1 is: wherein R 6 is as defined in any of the embodiments herein.
  • W in compounds of formula I or formula I-1 is: wherein R 6 is as defined in any of the embodiments herein.
  • W in compounds of formula I or formula I-1 is: wherein R 6 is as defined in any of the embodiments herein.
  • the present invention provides a compound of formula Ij: wherein:
  • z is 1.
  • R 5′ is hydrogen and R 5 is:
  • R 5′ is hydrogen and R 5 is:
  • the present invention provides a compound of formula IK: wherein:
  • the present invention provides a compound of formula IK-1: wherein:
  • R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12′ , R 12 , X, and V are as defined in any of the embodiments herein, z is 1, and NR 6 R 6 is:
  • R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12′ , R 12 , X, and V are as defined in any of the embodiments herein and z is 1.
  • the present invention provides a compound of formula IK-2: wherein:
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • R 5′ and R 5 are:
  • R 7 if present, and R 2 , R 4 , and R 12′ are each independently H, methyl, ethyl, or propyl.
  • R 7 if present, and R 2 and R 4 are each H.
  • the present invention provides a compound of formula IL: wherein:
  • the present invention provides a compound of formula IL-1: wherein:
  • R 1 , R 3 , R 6 , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12′ , R 12 , z, X, and V are as defined in any of the embodiments herein, and NR 6 R 6 is:
  • z is one, R 1 , R 3 , R 6 , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12′ , R 12 , X, and V are as defined in any of the embodiments herein, and NR 6 R 6 is:
  • the present invention provides a compound of formula IL-2: wherein:
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • R 3 is:
  • R 3 is:
  • R 3 is:
  • the present invention provides a compound of formula IM: wherein:
  • the present invention provides a compound of formula IM-1: wherein:
  • the present invention provides a compound of formula IM-2: wherein:
  • the present invention provides a compound of formula IM-3: wherein:
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • R 1 is:
  • R 1 is:
  • R 1 is cyclohexyl
  • the present invention provides a compound of formula IN: wherein:
  • the present invention provides a compound of formula IN-1: wherein:
  • R 6 , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12′ , R 12 , X and V are as defined in any of the embodiments herein, and NR 6 R 6 is:
  • the present invention provides a compound of formula IN-2: wherein:
  • the present invention provides a compound of formula IN-3: wherein:
  • z is one, W is selected from: and R 6 and R 8 are as defined in any of the embodiments herein.
  • W is selected from: and R 14 and R 15 are as defined in any of the embodiments herein.
  • optional J substituents on any substitutable nitrogen are selected from —R′, —N(R′) 2 , —N(R′)SO 2 R′, —SO 2 R′, —SO 2 N(R′) 2 , —C(O)R′, —C(O)OR′, —C(O)C(O)R′, —C(O)C(O)N(R′) 2 , —C(O)CH 2 C(O)R′, —C( ⁇ NH)N(R′) 2 , or —C(O)N(R′) 2 .
  • no carbon atoms of R 1 , R 3 , R 5 , and R 5′ are replaced with N. NH, O, or S.
  • these R 1 , R 3 , R 5 , and R 5′ groups have no J substituents.
  • the compound is:
  • the compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention.
  • Each stereogenic carbon may be of the R or S configuration.
  • the compounds of this invention have the structure and stereochemistry depicted in compounds 1-12.
  • Scheme 1 above provides a general route for the preparation of compounds of formula I, II, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL, IN, and IN wherein X-V is —C(O)C(O), W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and R 1 , R 3 , R 5 , R 5′ , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12 , and R 12′ are as described in any of the embodiments herein.
  • Scheme 2 above provides a general route for the preparation of compounds of formula 26.
  • commercially available amine 23 and sulfonyl chloride 24 are condensed and then hydrolyzed under basic conditions to provide intermediate acid 26.
  • amine 23 and sulfonyl chloride 24 are condensed and then hydrolyzed under basic conditions to provide intermediate acid 26.
  • suitable reagents may be used to prepare intermediate 26.
  • Scheme 3 above provides a general route for the preparation of compounds of formula III and formula I.
  • coupling of the acid 26 and amine 20 to give amide intermediate 27 may be accomplished using the conditions indicated or coupling reagents known to one of skill in the art.
  • Subsequent oxidation of keto alcohol 27 with Dess Martin periodinane, or other oxidation conditions known to those skilled in the art affords compounds of formula III or formula I, wherein X-V is —C(O)S(O) 1-2 , W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and R 1 , R 3 , R 5 , R 5′ , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12 , and R 12′ are as described in any of the embodiments herein.
  • Scheme 6 above provides a general route for the preparation of compounds of formula I and formula VI, wherein X-V is —S(O) 1-2 C(O)—, W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and R 1 , R 3 , R 5 , R 5′ , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12 , and R 12′ are as described in any of the embodiments herein.
  • Chloroester 37 is prepared according to the methods described in J. Org. Chem ., pp. 2624-2629 (1979).
  • Scheme 7 above provides a general route for the preparation of compounds of formula IB-1, formula IB, and formula IC, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and n, Z, Z′, R 1 , R 3 , R 5 , R 5′ , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 12 , and R 12′ are as described in any of the embodiments herein.
  • other suitable and commercially available coupling reagents may be used to prepare intermediates 47, 49, 51, and 53.
  • Boc-P3-OH may alternatively be substituted with the commercial CBz protected amino acids.
  • Suitable deprotection conditions to remove the Cbz protecting groups are known to those skilled in the art.
  • the oxidation of intermediate 53 to compounds of formula IB-1 may be accomplished using other suitable conditions known to the skilled artisan.
  • Scheme 8 above provides a general route for the preparation of compounds of formula ID-1 and formula ID, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and R 1 , R 3 , R 5 , R 5′ , R 6 , R 12 , and R 12′ are as described in any of the embodiments herein. As would be recognized by any skilled practitioner, other suitable and commercially available coupling reagents may be used to prepare intermediates 56, 58, 60, and 62.
  • Boc-P3-OH may alternatively be substituted with the commercial CBz protected amino acids.
  • Suitable deprotection conditions to remove the Cbz protecting groups are known to those skilled in the art.
  • the oxidation of intermediate 62 to compounds of formula ID-1 may be accomplished using other suitable conditions known to the skilled artisan.
  • Scheme 9 above provides a general route for the preparation of compounds of formula IE-1 and formula IE, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R 6 ) 2 , R 2 R 4 , and R 7 are H, and R′, R 1 , R 3 , R 5 , R 5′ , R 6 , R 12 and R 12′ are as described in any of the embodiments herein.
  • the steps used in scheme 9 could be modified by, for example, using different reagents or carrying out the reactions in a different order.
  • other suitable and commercially available coupling reagents may be used to prepare intermediates 66, 67, 69, and 70.
  • Cbz protected amino acids represented by, for instance, Cbz-P3-OH
  • Cbz-P3-OH may alternatively be substituted with the commercial t-Boc protected amino acids.
  • Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art.
  • the oxidation of intermediate 70 to compounds of formula IE-1 may be accomplished using other suitable conditions known to the skilled artisan.
  • Scheme 10 above depicts an alternative approach to preparing compounds of formulae IE-1 and IE of this invention wherein, X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and R′, R 1 , R 3 , R 5 , R 5′ , R 6 , R 12 , and R 12′ are as described in any of the embodiments herein.
  • a 4-hydroxyproline derivative 71 is reacted with a commercially available R′-halide (such an aryl chloride), represented by R′—X, in the presence of a suitable base (such as potassium t-butoxide) to provide a compound 72.
  • R′-halide such an aryl chloride
  • a suitable base such as potassium t-butoxide
  • the compound 72 then may be carried on to compounds of formula IE-1 by routine methods.
  • other suitable and commercially available coupling reagents may be used to prepare intermediates 74, 75, 76, and 77.
  • the commercially available Boc protected amino acids represented by, for instance, Boc-P3-OH, may alternatively be substituted with the commercial CBz protected amino acids. Suitable deprotection conditions to remove the Cbz protecting groups are known to those skilled in the art.
  • the oxidation of intermediate 77 to compounds of formula IE-1 may be accomplished using other suitable conditions known to the skilled artisan.
  • Scheme 11 above provides a general route for the preparation of compounds of formula IF-1 and formula IF, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R 6 ) 2 , R 2 , R 4 , and R 7 are H, and ring A, R 1 , R 3 , R 5 , R 5′ , R 6 , R 12 , and R 12′ are as described in any of the embodiments herein.
  • the steps used in scheme 11 could be modified by, for example, using different reagents or carrying out the reactions in a different order.
  • Scheme 12 above provides a synthetic route for the preparation of compound 84.
  • Scheme 12 could be modified using techniques known to skilled practitioners to arrive at compound 84.
  • other commercially available oxalamide esters may be converted into the corresponding acids by a route analogous to that described above.
  • Scheme 13 provides a synthetic route for the preparation of non-commercially available oxalamide esters or oxalamide acids of interest. Scheme 13 may be modified using techniques known to skilled practitioners to arrive at compounds represented by formula 88.
  • Scheme 14 above provides a synthetic route for the preparation of compound 1 from 89 (BOC-protected octahydro-indole-2-carboxylic acid).
  • Intermediate 89 may be prepared from commercially available octahydro-indole-2-carboxylic acid (Bachem) according to the procedure described in PCT publication No. WO 03/087092 (the entire of contents of which is hereby incorporated by reference) and references cited therein.
  • Scheme 14 could be modified using techniques known to skilled practitioners to arrive at compound 1.
  • the experimental procedures to prepare compound 1 are further exemplified below in Example 2.
  • Scheme 15 above provides a synthetic route for the preparation of Cbz-protected azabicyclo[2.2.1]heptane-3-carboxylic acid, compound 99 and the corresponding t-butyl ester, compound 100.
  • the free acid 99 may be further elaborated by the route defined in scheme 1 above to prepare compounds of formulae I and IH.
  • the t-butyl ester 100 may be further elaborated by a modification of schemes 9 or 10 above to give compounds of formulae I and IH.
  • Scheme 16 above provides a general route for the preparation of compounds of formula IP and formula I-1, wherein R 5 is H, R 5′ is n-propyl, W is —C(O)C(O)—NH—C(R 14 )—C(O)—NH—C(R 15 )—Y, R 2 , R 4 , and R 7 are H, and ring A, X, V, R 1 , R 3 , R 5 , R 5′ , R 6 , R 9 , R 9′ , R 10 , R 10′ , R 11 , R 11′ , R 14 , R 15 , Y, z, R 12 , and R 12′ are as described in any of the embodiments herein.
  • Various 3, 4, and 5-substituted proline analogues may either be purchased commercially or prepared according to known literature procedures.
  • the starting 3-substituted proline analogues may be prepared according to the method of Holladay, M. W. et al., J. Med. Chem., 34, pp. 457-461 (1991).
  • the cyclohexyl proline intermediates may be prepared by platinum oxide reduction of the commercially available phenyl substituted proline analogues. Such reduction conditions are well known to those skilled in the art.
  • the starting 3,4-disubstituted proline analogues may be prepared according to the method of Kanamasa, S. et al., J. Org. Chem, 56, pp.
  • one embodiment of this invention provides a process for preparing a compound of formula I, as defined in any of the embodiments herein, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII to provide a compound of formula IX: wherein:
  • the 4-hydroxy group in formula VII may be converted to a leaving group.
  • X is a nucleophilic oxygen which reacts with VII to provide IX.
  • P1, P3, P4 refer to the residues of an HCV protease inhibitor as defined in the art and as are well known to skilled practitioners.
  • the compound of formula IX may be carried on to a compound of formula I according to the methods described herein.
  • Another embodiment of this invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula I or formula I-1 or pharmaceutically acceptable salts thereof.
  • the compound of formula I or formula I-1 is present in an amount effective to decrease the viral load in a sample or in a patient, wherein said virus encodes a serine protease necessary for the viral life cycle, and a pharmaceutically acceptable carrier.
  • salts of the compounds of this invention are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, peroxine salt, sodium bicarbonate, sodium bicarbonate
  • Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides
  • dialkyl sulfates such as dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such
  • compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • ion exchangers alumina, aluminum stearate, lecithin
  • serum proteins such as human serum albumin
  • buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial g
  • compositions of this invention are formulated for pharmaceutical administration to a mammal.
  • said mammal is a human being.
  • compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir.
  • parenteral as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques.
  • the compositions are administered orally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • a long-chain alcohol diluent or dispersant such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions.
  • Other commonly used surfactants such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • dosage levels of between about 0.01 and about 100 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease.
  • dosage levels of between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease.
  • the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
  • the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration.
  • a typical preparation will contain from about 5% to about 95% active compound (w/w). In one embodiment, such preparations contain from about 20% to about 80% active compound.
  • compositions of this invention comprise a combination of a compound of formula I or formula I-1 and one or more additional therapeutic or prophylactic agents
  • both the compound and the additional agent should be present at dosage levels of between about 10 to 100% of the dosage normally administered in a monotherapy regimen.
  • the additional agent should be present at dosage levels of between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions.
  • carriers that are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • suppositories may be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug.
  • suitable non-irritating excipient include cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water.
  • the pharmaceutical compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride.
  • the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • compositions of this invention may also be administered by nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • the pharmaceutical compositions are formulated for oral administration.
  • compositions of this invention additionally comprise another anti-viral agent, preferably an anti-HCV agent.
  • anti-viral agents include, but are not limited to, immunomodulatory agents, such as ⁇ -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- ⁇ compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., compounds of U.S.
  • PEG-Intron means PEG-Intron®, peginteferon alfa-2b, available from Schering Corporation, Kenilworth, N.J.;
  • interferon means a member of a family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation, and modulate immune response, such as interferon alpha, interferon beta, or interferon gamma.
  • the interferon is ⁇ -interferon.
  • a therapeutic combination of the present invention utilizes natural alpha interferon 2a.
  • the therapeutic combination of the present invention utilizes natural alpha interferon 2b.
  • the therapeutic combination of the present invention utilizes recombinant alpha interferon 2a or 2b.
  • the interferon is pegylated alpha interferon 2a or 2b.
  • Interferons suitable for the present invention include:
  • a protease inhibitor would be preferably administered orally. Interferon is not typically administered orally. Nevertheless, nothing herein limits the methods or combinations of this invention to any specific dosage forms or regime. Thus, each component of a combination according to this invention may be administered separately, together, or in any combination thereof.
  • the protease inhibitor and interferon are administered in separate dosage forms.
  • any additional agent is administered as part of a single dosage form with the protease inhibitor or as a separate dosage form.
  • the specific amounts of each compound may be dependent on the specific amounts of each other compound in the combination.
  • dosages of interferon are typically measured in IU (e.g., about 4 million IU to about 12 million IU).
  • agents whether acting as an immunomodulatory agent or otherwise
  • agents include, but are not limited to, interferon-alph 2B (Intron A, Schering Plough); Rebatron (Schering Plough, Inteferon-alpha 2B+Ribavirin); pegylated interferon alpha (Reddy, K. R. et al. “Efficacy and Safety of Pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C ( Hepatology, 33, pp. 433-438 (2001); consensus interferon (Kao, J.
  • Interferons may ameliorate viral infections by exerting direct antiviral effects and/or by modifying the immune response to infection.
  • the antiviral effects of interferons are often mediated through inhibition of viral penetration or uncoating, synthesis of viral RNA, translation of viral proteins, and/or viral assembly and release.
  • non-immunomodulatory or immunomodulatory compounds may be used in combination with a compound of this invention including, but not limited to, those specified in WO 02/18369, which is incorporated herein by reference (see, e.g., page 273, lines 9-22 and page 274, line 4 to page 276, line 11).
  • This invention may also involve administering a cytochrome P450 monooxygenase inhibitor.
  • CYP inhibitors may be useful in increasing liver concentrations and/or increasing blood levels of compounds that are inhibited by CYP.
  • any CYP inhibitor that improves the pharmacokinetics of the relevant NS3/4A protease may be used in a method of this invention.
  • CYP inhibitors include, but are not limited to, ritonavir (WO 94/14436), ketoconazole, troleandomycin, 4-methylpyrazole, cyclosporin, clomethiazole, cimetidine, itraconazole, fluconazole, miconazole, fluvoxamine, fluoxetine, nefazodone, sertraline, indinavir, nelfinavir, amprenavir, fosamprenavir, saquinavir, lopinavir, delavirdine, erythromycin, VX-944, and VX-497.
  • Preferred CYP inhibitors include ritonavir, ketoconazole, troleandomycin, 4-methylpyrazole, cyclosporin, and clomethiazole.
  • ritonavir see U.S. Pat. No. 6,037,157, and the documents cited therein: U.S. Pat. No. 5,484,801, U.S. application Ser. No. 08/402,690, and International Applications WO 95/07696 and WO 95/09614).
  • a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated.
  • the amount of active ingredients will also depend upon the particular described compound and the presence or absence and the nature of the additional anti-viral agent in the composition.
  • the invention provides a method for treating a patient infected with a virus characterized by a virally encoded serine protease that is necessary for the life cycle of the virus by administering to said patient a pharmaceutically acceptable composition of this invention.
  • the methods of this invention are used to treat a patient suffering from a HCV infection. Such treatment may completely eradicate the viral infection or reduce the severity thereof.
  • the patient is a human being.
  • the methods of this invention additionally comprise the step of administering to said patient an anti-viral agent preferably an anti-HCV agent.
  • anti-viral agents include, but are not limited to, immunomodulatory agents, such as ⁇ -, ⁇ -, and ⁇ -interferons, pegylated derivatized interferon- ⁇ compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in U.S. Pat. Nos. 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof
  • Such additional agent may be administered to said patient as part of a single dosage form comprising both a compound of this invention and an additional anti-viral agent.
  • the additional agent may be administered separately from the compound of this invention, as part of a multiple dosage form, wherein said additional agent is administered prior to, together with or following a composition comprising a compound of this invention.
  • the present invention provides a method of pre-treating a biological substance intended for administration to a patient comprising the step of contacting said biological substance with a pharmaceutically acceptable composition comprising a compound of this invention.
  • biological substances include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, etc; sperm and ova; bone marrow and components thereof, and other fluids to be infused into a patient such as saline, dextrose, etc.
  • the invention provides methods of treating materials that may potentially come into contact with a virus characterized by a virally encoded serine protease necessary for its life cycle.
  • This method comprises the step of contacting said material with a compound according to the invention.
  • materials include, but are not limited to, surgical instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); laboratory instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); blood collection apparatuses and materials; and invasive devices, such as shunts, stents, etc.
  • the compounds of this invention may be used as laboratory tools to aid in the isolation of a virally encoded serine protease.
  • This method comprises the steps of providing a compound of this invention attached to a solid support; contacting said solid support with a sample containing a viral serine protease under conditions that cause said protease to bind to said solid support; and eluting said serine protease from said solid support.
  • the viral serine protease isolated by this method is HCV NS3-NS4A protease.
  • R t (min) refers to the HPLC retention time, in minutes, associated with the compound.
  • the HPLC retention times listed were either obtained from the mass spec. data or using the following method:
  • Ethyl oxanilate 83 (Aldrich, 1.0 g, 1.0 eq) in 12 mL of THF was treated dropwise with a 1N NaOH solution (5.70 mL, 1.1 eq) resulting in a white precipitate. After stirring for 3 hours at RT, 0.5N HCl and ethyl acetate were added, the organic layer separated, washed with 0.5N HCl and brine and then dried over sodium sulfate, filtered, and concentrated to give 712 mg (68%) of N-phenyl oxalamic acid 84 as a white solid with consistent analytical data.
  • reaction mixture was concentrated in vacuo, diluted with ethyl acetate, the organic phase washed with 0.5N HCl, brine, saturated sodium bicarbonate solution, and brine, then dried over sodium sulfate, filtered, and concentrated in vacuo.
  • Acid 84 (20 mg, 1.4 eq) in CH 2 Cl 2 (1 mL) was treated with PyBOP (53 mg, 1.2 eq) and NMM (0.028 mL, 3.0 eq) and stirred for 5 minutes. To this was added a solution of oxalamide (50 mg, 1.0 eq) and NMM (0.028 mL, 3.0 eq) in CH 2 Cl 2 (1 mL) and the mixture stirred at room temperature overnight. The mixture was diluted with ethyl acetate, the organic phase washed with 0.5N HCl, brine, saturated bicarbonate solution, and brine, then dried over sodium sulfate, filtered and concentrated in vacuo.
  • Oxalamide 96 (24 mg, 1.0 eq) in CH 2 Cl 2 (1 mL) and t-BuOH (41 uL) was treated with Dess Martin periodinane (41 mg, 3.0 eq) and the suspension stirred at room temp. for 3 hours. Sodium thiosulfate was added and the mixture stirred for 15 minutes, then diluted with ethyl acetate, the organic phase washed with sodium bicarbonate solution and brine, then dried over anydrous sodium sulfate and concentrated in vacuo.
  • HCV hepatitis C virus
  • replicon cell monolayer was treated with a trypsin:EDTA mixture, removed, and then media A was diluted into a final concentration of 100,000 cells per ml wit. 10,000 cells in 100 ul were plated into each well of a 96-well tissue culture plate, and cultured overnight in a tissue culture incubator at 37° C.
  • RNA virus such as Bovine Viral Diarrhea Virus (BVDV)
  • BVDV Bovine Viral Diarrhea Virus
  • RNA extraction reagents such as reagents from RNeasy kits
  • Total RNA was extracted according the instruction of manufacturer with modification to improve extraction efficiency and consistency.
  • total cellular RNA including HCV replicon RNA, was eluted and stored at ⁇ 80° C. until further processing.
  • a Taqman real-time RT-PCR quantification assay was set up with two sets of specific primers and probe. One was for HCV and the other was for BVDV. Total RNA extractants from treated HCV replicon cells was added to the PCR reactions for quantification of both HCV and BVDV RNA in the same PCR well. Experimental failure was flagged and rejected based on the level of BVDV RNA in each well. The level of HCV RNA in each well was calculated according to a standard curve run in the same PCR plate. The percentage of inhibition or decrease of HCV RNA level due to compound treatment was calculated using the DMSO or no compound control as 0% of inhibition. The IC50 (concentration at which 50% inhibition of HCV RNA level is observed) was calculated from the titration curve of any given compound.
  • Buffer 50 mM HEPES, pH 7.8; 20% glycerol; 100 mM NaCl
  • Total assay volume was 100 ⁇ L.
  • X1 conc. in Reagent ( ⁇ L) assay Buffer 86.5 see above 5 mM KK4A 0.5 25 ⁇ M 1 M DTT 0.5 5 mM DMSO or inhibitor 2.5 2.5% v/v 50 ⁇ M tNS3 0.05 25 nM 250 ⁇ M 5AB 20 25 ⁇ M (initiate)
  • the buffer, KK4A, DTT, and tNS3 were combined; distributed 78 ⁇ L each into wells of 96 well plate. This was incubated at 30 C for ⁇ 5-10 min.
  • test compound 2.5 ⁇ L was dissolved in DMSO (DMSO only for control) and added to each well. This was incubated at room temperature for 15 min.
  • Solvent B HPLC grade acetonitrile+0.1% TFA Time Flow Max (min) % B (ml/min) press. 0 5 0.2 400 12 60 0.2 400 13 100 0.2 400 16 100 0.2 400 17 5 0.2 400
  • Table 1 below depicts Mass Spec., HPLC, Ki and IC 50 data for certain compounds of the invention.
  • Compounds with Ki's ranging from 0.25 ⁇ M to 1 ⁇ M are designated A.
  • Compounds with Ki's ranging from 0.1 ⁇ M to 0.25 ⁇ M are designated B.
  • Compounds with Ki's below 0.1 ⁇ M are designated C.
  • Compounds with IC 50 's ranging from 0.25 ⁇ M to 1 ⁇ M are designated A.
  • Compounds with IC 50 's ranging from 0.1 ⁇ M to 0.25 ⁇ M are designated B.
  • Compounds with IC 50 's below 0.1 ⁇ M are designated C.

Abstract

The present invention relates to compounds of formula I:
Figure US20050119189A1-20050602-C00001
 or a pharmaceutically acceptable salts thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are useful as antiviral agents. The invention further relates to pharmaceutically acceptable compositions comprising said compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • The present application claims the benefit, under 35 U.S.C. § 119, of U.S. Provisional patent application No. 60/504,405, filed Sep. 18, 2003, entitled “Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease”, the entire contents of which is hereby incorporated by reference.
    • TECHNICAL FIELD OF THE INVENTION
  • The present invention relates to compounds that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to pharmaceutical compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection. The invention also relates to processes for preparing the compounds and methods of treating an HCV infection in a patient by administering a pharmaceutical composition comprising a compound of this invention.
    • BACKGROUND OF THE INVENTION
  • Infection by hepatitis C virus (“HCV”) is a compelling human medical problem. HCV is recognized as the causative agent for most cases of non-A, non-B hepatitis, with an estimated human sero-prevalence of 3% globally [A. Alberti et al., “Natural History of Hepatitis C,” J. Hepatology, 31., (Suppl. 1), pp. 17-24 (1999)]. Nearly four million individuals may be infected in the United States alone [M. J. Alter et al., “The Epidemiology of Viral Hepatitis in the United States, Gastroenterol. Clin. North Am., 23, pp. 437-455 (1994); M. J. Alter “Hepatitis C Virus Infection in the United States,” J. Hepatology, 31., (Suppl. 1), pp. 88-91 (1999)].
  • Upon first exposure to HCV only about 20% of infected individuals develop acute clinical hepatitis while others appear to resolve the infection spontaneously. In almost 70% of instances, however, the virus establishes a chronic infection that persists for decades [S. Iwarson, “The Natural Course of Chronic Hepatitis,” FEMS Microbiology Reviews, 14, pp. 201-204 (1994); D. Lavanchy, “Global Surveillance and Control of Hepatitis C,” J. Viral Hepatitis, 6, pp. 35-47 (1999)]. This usually results in recurrent and progressively worsening liver inflammation, which often leads to more severe disease states such as cirrhosis and hepatocellular carcinoma [M. C. Kew, “Hepatitis C and Hepatocellular Carcinoma”, FEMS Microbiology Reviews, 14, pp. 211-220 (1994); I. Saito et. al., “Hepatitis C Virus Infection is Associated with the Development of Hepatocellular Carcinoma,” Proc. Natl. Acad. Sci. USA, 87, pp. 6547-6549 (1990)]. Unfortunately, there are no broadly effective treatments for the debilitating progression of chronic HCV.
  • The HCV genome encodes a polyprotein of 3010-3033 amino acids [Q. L. Choo, et. al., “Genetic Organization and Diversity of the Hepatitis C Virus.” Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991); N. Kato et al., “Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B Hepatitis,” Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990); A. Takamizawa et. al., “Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers,” J. Virol., 65, pp. 1105-1113 (1991)]. The HCV nonstructural (NS) proteins are presumed to provide the essential catalytic machinery for viral replication. The NS proteins are derived by proteolytic cleavage of the polyprotein [R. Bartenschlager et. al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions,” J. Virol., 67, pp. 3835-3844 (1993); A. Grakoui et. al., “Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Polyprotein Cleavage Sites,” J. Virol., 67, pp. 2832-2843 (1993); A. Grakoui et. al., “Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products,” J. Virol., 67, pp. 1385-1395 (1993); L. Tomei et. al., “NS3 is a serine protease required for processing of hepatitis C virus polyprotein”, J. Virol., 67, pp. 4017-4026 (1993)].
  • The HCV NS protein 3 (NS3) contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decrease viral infectivity [Chambers, T. J. et. al., “Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein”, Proc. Natl. Acad. Sci. USA, 87, pp. 8898-8902 (1990)]. The first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV polyprotein [C. Lin et al., “Hepatitis C Virus NS3 Serine Proteinase: Trans-Cleavage Requirements and Processing Kinetics”, J. Virol., 68, pp. 8147-8157 (1994)].
  • The HCV NS3 serine protease and its associated cofactor, NS4A, helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing. HIV protease inhibitors, which inhibit viral protein processing, are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents. Consequently HCV NS3 serine protease is also an attractive target for drug discovery.
  • There are not currently any satisfactory anti-HCV agents or treatments. Until recently, the only established therapy for HCV disease was interferon treatment. However, interferons have significant side effects [M. A. Wlaker et al., “Hepatitis C Virus: An Overview of Current Approaches and Progress,” DDT, 4, pp. 518-29 (1999); D. Moradpour et al., “Current and Evolving Therapies for Hepatitis C,” Eur. J. Gastroenterol. Hepatol., 11, pp. 1199-1202 (1999); H. L. A. Janssen et al. “Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis,” J. Hepatol., 21, pp. 241-243 (1994); P. F. Renault et al., “Side Effects of Alpha Interferon,” Seminars in Liver Disease, 9, pp. 273-277. (1989)] and induce long term remission in only a fraction (25%) of cases [O. Weiland, “Interferon Therapy in Chronic Hepatitis C Virus Infection”, FEMS Microbiol. Rev., 14, pp. 279-288 (1994)]. Recent introductions of the pegylated forms of interferon (PEG-Intron® and Pegasys®) and the combination therapy of ribavirin and pegylated interferon (Rebetrol®) have resulted in only modest improvements in remission rates and only partial reductions in side effects. Moreover, the prospects for effective anti-HCV vaccines remain uncertain.
  • Thus, there is a need for more effective anti-HCV therapies. Such inhibitors would have therapeutic potential as protease inhibitors, particularly as serine protease inhibitors, and more particularly as HCV NS3 protease inhibitors. Specifically, such compounds may be useful as antiviral agents, particularly as anti-HCV agents.
    • SUMMARY OF THE INVENTION
  • The present invention addresses these needs by providing a compound of formula I:
    Figure US20050119189A1-20050602-C00002
    or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.
  • The invention also relates to compounds of formula I-1:
    Figure US20050119189A1-20050602-C00003
    or pharmaceutically acceptable salts thereof, wherein the variables are as defined herein.
  • The invention also relates to compositions that comprise the above compounds and the use thereof. Such compositions may be used to pre-treat invasive devices to be inserted into a patient, to treat biological samples, such as blood, prior to administration to a patient, and for direct administration to a patient. In each case the composition will be used to inhibit HCV replication and to lessen the risk of or the severity of HCV infection.
  • The invention also relates to processes for preparing the compounds of formula I.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The present invention provides a compound of formula I:
    Figure US20050119189A1-20050602-C00004
    or a pharmaceutically acceptable salt thereof,
    wherein:
    • R9 and R9′ are independently:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to three aliphatic carbon atoms in each of R9 and R9′ may be replaced by O, N, NH, S, SO, or SO2;
        • wherein each of R9 and R9′ is independently and optionally substituted with up to 3 substituents independently selected from J;
        • J is halogen, —OR′, —NO2, —CN, —CF3, —OCF3, —R′, oxo, thioxo, ═N(R′), ═N(OR′), 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R′)2, —SR′, —SOR′, —SO2R′, —SO2N(R′)2, —SO3R′, —C(O)R′, —C(O)C(O)R′, —C(O)C(O)OR′, —C(O)C(O)N(R′)2, —C(O)CH2C(O)R′, —C(S)R′, —C(S)OR′, —C(O)OR′, —OC(O)R′, —C(O)N(R′)2, —OC(O)N(R′)2, —C(S)N(R′)2, —(CH2)0-2NHC(O)R′, —N(R′)N(R′)COR′, —N(R′)N(R′)C(O)OR′, —N(R′)N(R′)CON(R′)2, —N(R′)SO2R′, —N(R′)SO2N(R′)2, —N(R′)C(O)OR′, —N(R′)C(O)R′, —N(R′)C(S)R′, —N(R′)C(O)N(R′)2, —N(R′)C(S)N(R′)2, —N(COR′)COR′, —N(OR′)R′, —C(═NH)N(R′)2, —C(O)N(OR′)R′, —C(═NOR′)R′, —OP(O)(OR′)2, —P(O)(R′)2, —P(O)(OR′)2, or —P(O)(H)(OR′); wherein;
          • R′ is independently selected from:
          • hydrogen-,
          • (C1-C12)-aliphatic-,
          • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
          • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
          • (C6-C10)-aryl-,
          • (C6-C10)-aryl-(C1-C12)aliphatic-,
          • (C3-C10)-heterocyclyl-,
          • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
          • (C5-C10)-heteroaryl-, or
          • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
          • wherein up to 5 atoms in R′ are optionally and independently substituted with J;
          • wherein two R′ groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
    • R10, R10′, R11, and R11′ are each independently:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
        • wherein up to 3 aliphatic carbon atoms in each of R10, R10′, R11, and R11′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein each of R10, R10′, R11, and R11′ is independently and optionally substituted with up to 3 substituents independently selected from J; or
    • R10 is —OR′ and R10 is H; or
    • R10 and R10′ are both —OR′ or —SR′; or
    • R10 and R10′ are both fluorine; or
    • R10 and R10′ are taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring;
      • wherein the R10 and R10′ atoms bound to the carbon atom are independently C(H), N, NH, O, S, SO, or SO2;
      • wherein said ring may contain up to 4 heteroatoms independently selected from N, NH, O, S, SO, and SO2;
      • wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and
      • wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or
    • R9 and R10 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
    • R10 and R11 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
    • R9 and R11 are taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, O, S, SO, or SO2;
    • R1 and R3 are independently:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to 3 aliphatic carbon atoms in each of R1 and R3 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein each of R1 and R3 is independently and optionally substituted with up to 3 substituents independently selected from J;
    • R2, R4, and R7 are each independently:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or
      • (C6-C10)-aryl-(C1-C12)-aliphatic-;
        • wherein up to two aliphatic carbon atoms in each of R2, R4, and R7 may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
        • wherein each of R2, R4, and R7 is optionally substituted with up to 3 substituents independently selected from J;
    • R5 and R5′ are independently hydrogen or (C1-C12)-aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R5 is Ph or —CH2Ph and R5′ is H, wherein said Ph or —CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or
    • R5 and R5′ together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, O, SO, and SO2; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;
    • W is:
      Figure US20050119189A1-20050602-C00005
      • wherein each R6 is independently:
        • hydrogen-,
        • (C1-C12)-aliphatic-,
        • (C6-C10)-aryl-,
        • (C6-C10)-aryl-(C1-C12)aliphatic-,
        • (C3-C10)-cycloalkyl- or cycloalkenyl-,
        • [(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,
        • (C3-C10)-heterocyclyl-,
        • (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
        • (C5-C10)-heteroaryl-, or
        • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-,
        • wherein R6 is optionally substituted with up to 3 J substituents; or
      • two R6 groups, together with the nitrogen atom to which they are bound, optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
      • wherein each R8 is independently —OR′; or the R8 groups together with the boron atom, optionally form a (C3-C10)-membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR′, O, SO, and SO2;
    • X is —C(O)—, —S(O)—, or —S(O)2—,
    • V is —C(O)—, —S(O)—, —S(O)2—, or —N(R13)—;
      • wherein R13 is:
        • hydrogen-,
        • (C1-C12)-aliphatic-,
        • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
        • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
        • (C6-C10)-aryl-,
        • (C6-C10)-aryl-(C1-C12)aliphatic-,
        • (C3-C10)-heterocyclyl-,
        • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
        • (C5-C10)-heteroaryl-, or
        • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
          • wherein up to two aliphatic carbon atoms in R13 may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
          • wherein R13 is independently and optionally substituted with up to 3 substituents independently selected from J;
    • R12 and R12′ are independently:
      • hydrogen;
      • (C1-C12)-aliphatic-;
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-cycloalkyl or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to 3 aliphatic carbon atoms in each of R12 or R12′ may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
          • wherein each of R12 or R12′ is optionally substituted with up to 3 substituents independently selected from J; or
    • R12 and R12′ together with the nitrogen atom to which they are bound, form a (C3-C10)-heterocyclic ring;
      • wherein said (C3-C10)-heterocyclic ring is optionally substituted with up to 3 substituents independently selected from J.
  • The present invention also provides a compound of formula I-1:
    Figure US20050119189A1-20050602-C00006
    or a pharmaceutically acceptable salt thereof,
    wherein:
    • z is 0 or 1;
    • R9 and R9′ are independently:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to three aliphatic carbon atoms in each of R9 and R9′, may be replaced by O, N, NH, S, SO, or SO2;
        • wherein each of R9 and R9′ is independently and optionally substituted with up to 3 substituents independently selected from J;
        • J is halogen, —OR′, —NO2, —CN, —CF3, —OCF3, —R′, oxo, thioxo, ═N(R′), ═N(OR′), 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R′)2, —SR′, —SOR′, —SO2R′, —SO2N(R′)2, —SO3R′, —C(O)R′, —C(O)C(O)R′, —C(O)C(O)OR′, —C(O)C(O)N(R′)2, —C(O)CH2C(O)R′, —C(S)R′, —C(S)OR′, —C(O)OR′, —OC(O)R′, —C(O)N(R′)2, —OC(O)N(R′)2, —C(S)N(R′)2, —(CH2)0-2NHC(O)R′, —N(R′)N(R′)COR′, —N(R′)N(R′)C(O)OR′, —N(R′)N(R′)CON(R′)2, —N(R′)SO2R′, —N(R′)SO2N(R′)2, —N(R′)C(O)OR′, —N(R′)C(O)R′, —N(R′)C(S)R′, —N(R′)C(O)N(R′)2, —N(R′)C(S)N(R′)2, —N(COR′)COR′, —N(OR′)R′, —C(═NH)N(R′)2, —C(O)N(OR′)R′, —C(═NOR′)R′, —OP(O)(OR′)2, —P(O)(R′)2, —P(O)(OR′)2, or —P(O)(H)(OR′); wherein;
          • R′ is independently selected from:
          • hydrogen-,
          • (C1-C12)-aliphatic-,
          • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
          • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
          • (C6-C10)-aryl-,
          • (C6-C10)-aryl-(C1-C12)aliphatic-,
          • (C3-C10)-heterocyclyl-,
          • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
          • (C5-C10)-heteroaryl-, or
          • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
          • wherein up to 5 atoms in R′ are optionally and independently substituted with J;
          • wherein two R′ groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
    • R10, R10′, R11, and R11′ are each independently:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
        • wherein up to 3 aliphatic carbon atoms in each of R10, R10′, R11, and R11′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein each of R10, R10′, R11, and R11′ is independently and optionally substituted with up to 3 substituents independently selected from J; or
    • R10 is —OR′ and R10′ is H; or
    • R10 and R10′ are both —OR′ or —SR′; or
    • R10 and R10′ are both fluorine; or
    • R10 and R10′ are taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring;
      • wherein the R10 and R10′ atoms bound to the carbon atom are independently C(H), N, NH, O, S, SO, or SO2;
      • wherein said ring may contain up to 4 heteroatoms independently selected from N, NH, O, S, SO, and SO2;
      • wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and
      • wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or
    • R9 and R10 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
    • R10 and R11 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
    • R9 and R11 are taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, O, S, SO, or SO2;
    • R1 (if present) and R3 are independently:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to 3 aliphatic carbon atoms in each of R1 (if present) and R3 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein each of R1 (if present) and R3 is independently and optionally substituted with up to 3 substituents independently selected from J;
    • R2, R4, and R7 (if present) are each independently:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or
      • (C6-C10)-aryl-(C1-C12)-aliphatic-;
        • wherein up to two aliphatic carbon atoms in each of R2, R4, and R7 (if present) may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
        • wherein each of R2, R4, and R7 (if present) is optionally substituted with up to 3 substituents independently selected from J;
    • R5 and R5′ are independently hydrogen or (C1-C12)-aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R5 is Ph or —CH2Ph and R5′ is H, wherein said Ph or —CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or
    • R5 and R5′ together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, O, SO, and SO2; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;
    • W is:
      Figure US20050119189A1-20050602-C00007
      • wherein
      • Y is —CO2H, a derivative of —CO2H, or a bioisostere of —CO2H;
      • each R6 is independently:
        • hydrogen-,
        • (C1-C12)-aliphatic-,
        • (C6-C10)-aryl-,
        • (C6-C10)-aryl-(C1-C12)aliphatic-,
        • (C3-C10)-cycloalkyl- or cycloalkenyl-,
        • [(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,
        • (C3-C10)-heterocyclyl-,
        • (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
        • (C5-C10)-heteroaryl-, or
        • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-,
        • wherein R6 is optionally substituted with up to 3 J substituents; or
      • two R6 groups, together with the nitrogen atom to which they are bound, optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
      • wherein each R8 is independently —OR′; or the R8 groups together with the boron atom, optionally form a (C3-C10)-membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR′, O, SO, and SO2;
    • X is —C(O)—, —S(O)—, or —S(O)2—,
    • V is —C(O)—, —S(O)—, —S(O)2—, or —N(R13)—;
      • wherein R13 is:
        • hydrogen-,
        • (C1-C12)-aliphatic-,
        • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
        • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
        • (C6-C10)-aryl-,
        • (C6-C10)-aryl-(C1-C12)aliphatic-,
        • (C3-C10)-heterocyclyl-,
        • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
        • (C5-C10)-heteroaryl-, or
        • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
          • wherein up to two aliphatic carbon atoms in R13 may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
          • wherein R13 is independently and optionally substituted with up to 3 substituents independently selected from J;
    • R12 and R12′ are independently:
      • hydrogen;
      • (C1-C12)-aliphatic-;
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-cycloalkyl or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to 3 aliphatic carbon atoms in each of R12 or R12′ may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
          • wherein each of R12 or R12′ is optionally substituted with up to 3 substituents independently selected from J; or
    • R12 and R12′ together with the nitrogen atom to which they are bound, form a (C3-C10)-heterocyclic ring;
      • wherein said (C3-C10)-heterocyclic ring is optionally substituted with up to 3 substituents independently selected from J; and
    • R14 and R15 are independently:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-(C1-C12)aliphatic-,
        • wherein up to 3 aliphatic carbon atoms in R14 and R15 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein each of R14 and R15 is independently and optionally substituted at each substitutable position with up to 3 substituents independently selected from J.
          Definitions
  • The term “aryl” as used herein means a monocyclic or bicyclic carbocyclic aromatic ring system. Phenyl is an example of a monocyclic aromatic ring system. Bicyclic aromatic ring systems include systems wherein both rings are aromatic, e.g., naphthyl, and systems wherein only one of the two rings is aromatic, e.g., tetralin. It is understood that as used herein, the term “(C6-C10)-aryl-” includes any one of a C6, C7, C8, C9, and C10 monocyclic or bicyclic carbocyclic aromatic ring system.
  • The term “bioisostere” —CO2H as used in herein refers to a chemical moiety which may substitute for a carboxylic acid group in a biologically active molecule. Examples of such groups are disclosed in Christopher A. Lipinski, “Bioisosteres in Drug Design” Annual Reports in Medicinal Chemistry, 21, pp. 286-88 (1986), and in C. W. Thornber, “Isosterism and Molecular Modification in Drug Design” Chemical Society Reviews, pp. 563-580 (1979). Examples of such groups include, but are not limited to, —COCH2OH, —CONHOH, SO2NHR′, —SO3H, —PO(OH)NH2, —CONHCN, —OSO3H, —CONHSO2R′, —PO(OH)2, —PO(OH)(OR′), —PO(OH)(R′), —OPO(OH)2, —OPO(OH)(OR′), —OPO(OH)(R′), HNPO(OH)2, —NHPO(OH) (OR′), —NHPO(OH) (R′)
    Figure US20050119189A1-20050602-C00008
  • The term “heterocyclyl” as used herein means a monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatom or heteroatom groups in each ring selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement. In a bicyclic non-aromatic ring system embodiment of “heterocyclyl” one or both rings may contain said heteroatom or heteroatom groups. It is understood that as used herein, the term “(C5-C10)-heterocyclyl-” includes any one of a 5, 6, 7, 8, 9, and 10 atom monocyclic or bicyclic non-aromatic ring system having 1 to 3 heteroatoms or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
  • Examples of heterocyclic rings include 3-1H-benzimidazol-2-one, 3-(1-alkyl)-benzimidazol-2-one, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothiophenyl, 3-tetrahydrothiophenyl, 2-morpholino, 3-morpholino, 4-morpholino, 2-thiomorpholino, 3-thiomorpholino, 4-thiomorpholino, 1-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 1-tetrahydropiperazinyl, 2-tetrahydropiperazinyl, 3-tetrahydropiperazinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 1-pyrazolinyl, 3-pyrazolinyl, 4-pyrazolinyl, 5-pyrazolinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2-thiazolidinyl, 3-thiazolidinyl, 4-thiazolidinyl, 1-imidazolidinyl, 2-imidazolidinyl, 4-imidazolidinyl, 5-imidazolidinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, benzothiolane, benzodithiane, and 1,3-dihydro-imidazol-2-one.
  • The term “heteroaryl” as used herein means a monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatoms or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement. In such a bicyclic aromatic ring system embodiment of “heteroaryl”:
      • one or both rings may be aromatic; and
      • one or both rings may contain said heteroatom or heteroatom groups. It is understood that as used herein, the term “(C5-C10)-heteroaryl-” includes any one of a 5, 6, 7, 8, 9, and 10 atom monocyclic or bicyclic aromatic ring system having 1 to 3 heteroatoms or heteroatom groups in each ring selected from O, N, NH, and S in a chemically stable arrangement.
  • Examples of heteroaryl rings include 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, benzimidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, benzofuryl, benzothiophenyl, indolyl (e.g., 2-indolyl), pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5-thiadiazolyl, purinyl, pyrazinyl, 1,3,5-triazinyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), and isoquinolinyl (e.g., 1-isoquinolinyl, 3-isoquinolinyl, or 4-isoquinolinyl).
  • The term “aliphatic” as used herein means a straight chained or branched alkyl, alkenyl or alkynyl. It is understood that as used herein, the term “(C1-C12)-aliphatic-” includes any one of a C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, and C12 straight or branched alkyl chain of carbon atoms. It is also understood that alkenyl or alkynyl embodiments need at least two carbon atoms in the aliphatic chain. The term “cycloalkyl or cycloalkenyl” refers to a monocyclic or fused or bridged bicyclic carbocyclic ring system that is not aromatic. Cycloalkenyl rings have one or more units of unsaturation. It is also understood that as used herein, the term “(C3-C10)-cycloalkyl- or -cycloalkenyl-” includes any one of a C3, C4, C5, C6, C7, C8, C9, and C10 monocyclic or fused or bridged bicyclic carbocyclic ring. Preferred cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, nornbornyl, adamantyl and decalin-yl.
  • As used herein, the carbon atom designations may have the indicated integer and any intervening integer. For example, the number of carbon atoms in a (C1-C4)-alkyl group is 1, 2, 3, or 4. It should be understood that these designation refer to the total number of atoms in the appropriate group. For example, in a (C3-C10)-heterocyclyl the total number of carbon atoms and heteroatoms is 3 (as in aziridine), 4, 5, 6 (as in morpholine), 7, 8, 9, or 10.
  • The phrase “chemically stable arrangement” as used herein refers to a compound structure that renders the compound sufficiently stable to allow manufacture and administration to a mammal by methods known in the art. Typically, such compounds are stable at a temperature of 40° C. or less, in the absence of moisture or other chemically reactive condition, for at least a week.
    • EMBODIMENTS
  • According to one embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00009
    radical is:
    Figure US20050119189A1-20050602-C00010
    wherein:
    • R12, R12′, and R13 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00011
    radical is:
    Figure US20050119189A1-20050602-C00012
    wherein:
      • R12′ is hydrogen;
      • R12 is:
      • (C1-C12)-aliphatic-;
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-cycloalkyl or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein R12 is optionally substituted with up to 3 substituents independently selected from J; and
      • R13 is as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00013
    radical is:
    Figure US20050119189A1-20050602-C00014
    wherein:
      • R12′ is hydrogen;
    • R12 is:
      • (C1-C12)-aliphatic-;
      • (C6-C10)-aryl-(C1-C12) aliphatic-, or
      • (C3-C10)-cycloalkyl or -cycloalkenyl-;
        • wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
        • wherein R12 is optionally substituted with up to 3 substituents independently selected from J; and
      • R13 is as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00015
    radical is:
    Figure US20050119189A1-20050602-C00016
    wherein:
      • R12′ is hydrogen; and
      • R12 is:
      • (C1-C12)-aliphatic-;
      • (C6-C10)-aryl-(C1-C12) aliphatic-, or
      • (C3-C10)-cycloalkyl or -cycloalkenyl-;
        • wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement; and
        • wherein R12 is optionally substituted with up to 3 substituents independently selected from J.
  • According to another embodiment for compounds of formula I and formula I-1, the
    Figure US20050119189A1-20050602-C00017
    radical is;
    Figure US20050119189A1-20050602-C00018
      • In another embodiment for compounds of formula I or formula I-1, the
        Figure US20050119189A1-20050602-C00019
        radical is;
        Figure US20050119189A1-20050602-C00020
  • According to another embodiment, the present invention provides a compound of formula IA:
    Figure US20050119189A1-20050602-C00021
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R10, R10′, R11, R11′, R12, z, and W are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IA, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00022
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IA, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00023
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00024
    radical is:
    Figure US20050119189A1-20050602-C00025
    wherein:
      • R12, and R12′ are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00026
    radical is:
    Figure US20050119189A1-20050602-C00027
    wherein:
      • R12′ is hydrogen; and
      • R12 is:
      • (C1-C12)-aliphatic-;
      • (C6-C10)-aryl-(C1-C12)aliphatic-, or
      • (C3-C10)-cycloalkyl or -cycloalkenyl-;
        • wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement; and
        • wherein R12 is optionally substituted with up to 3 substituents independently selected from J.
  • In certain embodiments of formula I, wherein z is 1 and the
    Figure US20050119189A1-20050602-C00028
    radical is attached to N(R7), R7 is hydrogen.
  • In certain embodiments of formula I-1, wherein z is 1 and the
    Figure US20050119189A1-20050602-C00029
    radical is attached to N(R7), R7 is hydrogen.
  • In certain other embodiments for compounds of formula I-1, wherein z is 0 and the
    Figure US20050119189A1-20050602-C00030
    radical is attached to N(R2), R2 is hydrogen.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00031
    radical is:
    Figure US20050119189A1-20050602-C00032
    wherein:
      • n is 0, 1, or 2;
      • Z and Z′ are independently C(H), N, NH, O, or S;
      • R9, R9′, R11, and R11′ are as defined in any of the embodiments herein; and
      • the spirocyclic ring containing Z and Z′ is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or I-1, the
    Figure US20050119189A1-20050602-C00033
    radical is:
    Figure US20050119189A1-20050602-C00034
    wherein:
      • R11 and R11′ are both H;
      • n is 0, 1, or 2;
      • R9 and R9′ are as defined in any of the embodiments herein; and
      • the spirocyclic ring containing Z and Z′ is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or I-1, the
    Figure US20050119189A1-20050602-C00035
    radical is:
    Figure US20050119189A1-20050602-C00036
    wherein:
      • n is 0 or 1.
  • According to another embodiment, the present invention provides a compound of formula IB:
    Figure US20050119189A1-20050602-C00037
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R11, R11′, R12, z, Z, Z′, n, and W are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IB-1:
    Figure US20050119189A1-20050602-C00038
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R11, R11′, R12, R12′, X, V, n, z, Z, Z′, and W are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IB or formula IB-1, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00039
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IB or formula IB-1, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00040
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00041
    radical is:
    Figure US20050119189A1-20050602-C00042
    wherein:
      • Z and Z′ are independently C(H), N, NH, O, or S;
      • R9, R9′, R11, and R11′ are as defined in any of the embodiments herein; and
      • the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IC:
    Figure US20050119189A1-20050602-C00043
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R11, R11′, R12, z, Z, Z′, and W are as defined in any of the embodiments herein; and
      • the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IC, z is 1, Z and Z′ are S, R9, R9′, R11, and R11′, are H, R1, R2, R3, R4, R5, R5′, R7, R12, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • In another embodiment for compounds of formula IC, z is 0, Z and Z′ are S, R9, R9′, R11, and R11′ are H, R1, R2, R3, R4, R5, R5′, R7, R12, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IC-1:
    Figure US20050119189A1-20050602-C00044
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R11, R11′, R12, R12′, X, V, z, Z, Z′ and W are as defined in any of the embodiments herein; and
      • the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IC-1, z is 1, Z and Z′ are S, R9, R9′, R11, and R11′ are H, R1, R2, R3, R4, R5, R5′, R7, R12, R12′, X, V, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • In another embodiment for compounds of formula IC-1, z is 0, Z and Z′ are S, R9, R9′, R11, and R11′ are H, R1, R2, R3, R4, R5, R5′, R7, R12, R12′, X, V, and W are as defined in any of the embodiments herein and the fused benzo ring is optionally substituted with up to 3 J substituents, wherein J is as defined in any of the embodiments herein.
  • According to yet another embodiment for compounds of formula IC or formula IC-1, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00045
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to still another embodiment for compounds of formula IC or formula IC-1, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00046
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00047
    radical is:
    Figure US20050119189A1-20050602-C00048
    wherein:
      • R9, R9′, R11, and R11′ are H; and
      • R′ is selected from:
      • hydrogen-,
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • [(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-, or
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
      • wherein up to 5 atoms in R′ are optionally and independently substituted with J;
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00049
    radical is:
    Figure US20050119189A1-20050602-C00050
    wherein:
      • R9, R9′, R11, and R11′ are H.
  • In yet another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00051
    radical is:
    Figure US20050119189A1-20050602-C00052
    wherein:
    • R9, R9′, R11, and R11′, are H.
  • According to another embodiment, the present invention provides a compound of formula ID:
    Figure US20050119189A1-20050602-C00053
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R11, R11′, R12, z, and W are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula ID-1:
    Figure US20050119189A1-20050602-C00054
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R11, R11′, R12, R12′, X, V, z, and W are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula ID or formula ID-1, z is 1.
  • According to another embodiment for compounds of formula ID or formula ID-1, z is 0.
  • According to yet another embodiment for compounds of formula ID or formula ID-1, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00055
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula ID or formula ID-1, z is 0, w is selected from:
    Figure US20050119189A1-20050602-C00056
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, in the
    Figure US20050119189A1-20050602-C00057
    radical,
      • R9, R10, R10′, R11, and R11′ are H; and
      • R9′ is:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • (C6-C10)-aryl-,
      • (C3-C10)-heterocyclyl-, or
      • (C5-C10)-heteroaryl-;
      • wherein up to three aliphatic carbon atoms in R9′ may be replaced by O, N, NH, S, SO, or SO2;
      • wherein R9′ is independently and optionally substituted with up to 3 substituents independently selected from J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00058
    radical is:
    Figure US20050119189A1-20050602-C00059
  • According to another embodiment for compounds of formula I or formula I-1, in the
    Figure US20050119189A1-20050602-C00060
    radical
      • R9, R9′, R10, R11, and R11′ are H; and
      • R10′ is:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • (C6-C10)-aryl-,
      • wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
      • wherein up to 3 aliphatic carbon atoms in R10′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
      • wherein R10′, is independently and optionally substituted with up to 3 substituents independently selected from J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00061
    radical is:
    Figure US20050119189A1-20050602-C00062
    wherein the R10′ group, is independently and optionally substituted with up to 3 substituents independently selected from J.
  • According to yet another embodiment for compounds of formula I or formula I-1, in the
    Figure US20050119189A1-20050602-C00063
    radical
      • R9, R9′, R10, R10′, and R11 are H; and
      • R11′ is:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • (C6-C10)-aryl-,
      • wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
      • wherein up to 3 aliphatic carbon atoms in R11, may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
      • wherein R11′, is independently and optionally substituted with up to 3 substituents independently selected from J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00064
    radical is:
    Figure US20050119189A1-20050602-C00065
  • According to another embodiment for compounds of formula I or formula I-1, in the
    Figure US20050119189A1-20050602-C00066
    radical
      • R9, R10, R11, and R11′ are H; and
      • R9, and R10′ are:
      • (C1-C12)-aliphatic-,
      • (C3-C10)-cycloalkyl- or -cycloalkenyl-,
      • wherein up to 3 aliphatic carbon atoms in R9′ and R10′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
      • wherein R9′ and R10′ are independently and optionally substituted with up to 3 substituents independently selected from J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00067
    radical is:
    Figure US20050119189A1-20050602-C00068
  • According to another embodiment for compounds of formula I or formula I-1, in the
    Figure US20050119189A1-20050602-C00069
    radical
      • R9, R9′, R10′, R11, and R11′ are H; and
      • R′ is selected from:
      • (C6-C10)-aryl-,
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
      • (C5-C10)-heteroaryl-, and
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
      • wherein up to 5 atoms in R′ are optionally and independently substituted with J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00070
    radical is:
    Figure US20050119189A1-20050602-C00071
    Figure US20050119189A1-20050602-C00072
    Figure US20050119189A1-20050602-C00073
    Figure US20050119189A1-20050602-C00074
      • wherein up to 5 atoms in R′ are optionally and independently substituted with J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00075
    radical is:
    Figure US20050119189A1-20050602-C00076
    wherein up to 5 atoms in R′ are optionally and independently substituted with J.
  • According to another embodiment for compounds of formula I or formula I-1, the radical is:
    Figure US20050119189A1-20050602-C00077
  • According to yet another embodiment for compounds of formula I or formula I-1, in the
    Figure US20050119189A1-20050602-C00078
    radical
      • R9, R9′, R10′, R11, and R11′ are H; and
      • R′ is selected from:
      • (C6-C10)-aryl-(C1-C12)aliphatic-,
      • (C3-C10)-heterocyclyl-(C1-C12)aliphatic-, and
      • (C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
        • wherein up to 5 atoms in R′ are optionally and independently substituted with J.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00079
    radical is:
    Figure US20050119189A1-20050602-C00080
      • wherein up to 5 atoms in R′ are optionally and independently substituted with J.
  • According to another embodiment, the present invention provides a compound of formula IE:
    Figure US20050119189A1-20050602-C00081
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R10′, R′, R11, R11′, R12, z, and W are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IE-1:
    Figure US20050119189A1-20050602-C00082
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R10′, R′, R11, R11′. R12, R12′, z, X, V, and W are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IE or formula IE-1, z is 1.
  • According to another embodiment for compounds of formula IE or formula IE-1, z is 0.
  • According to yet another embodiment for compounds of formula IE or formula IE-1, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00083
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IE or formula IE-1, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00084
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00085
    radical is:
    Figure US20050119189A1-20050602-C00086
    wherein;
      • ring A is a 5- to 6-membered aromatic or 3- to 6-membered non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, SO, or SO2;
      • wherein said ring A is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
      • wherein any ring has up to 3 substituents selected independently from J; and
      • R9, R9′, R10′, and R11′ are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00087
    radical is:
    Figure US20050119189A1-20050602-C00088
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00089
    radical is:
    Figure US20050119189A1-20050602-C00090
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00091
    radical is:
    Figure US20050119189A1-20050602-C00092
  • According to yet another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00093
    radical is:
    Figure US20050119189A1-20050602-C00094
  • According to another embodiment, the present invention provides a compound of formula IF:
    Figure US20050119189A1-20050602-C00095
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R10′, R11′, R12, z, W, and ring A are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IF-1:
    Figure US20050119189A1-20050602-C00096
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9, R9′, R10, R11′, R12, R12′, z, X, V, W, and ring A are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IF-2:
    Figure US20050119189A1-20050602-C00097
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, z, X, V, and W, are as defined in any of the embodiments herein.
  • According to one embodiment of compounds of formula IF, formula IF-1, or formula IF-2, z is 1.
  • According to another embodiment of compounds of formula IF, formula IF-1, or formula IF-2, z is 0.
  • According to one embodiment for compounds of formula IF, formula IF-1, or formula IF-2, z is 1, w is selected from:
    Figure US20050119189A1-20050602-C00098
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IF, formula IF-1, or formula IF-2, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00099
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00100
    radical is:
    Figure US20050119189A1-20050602-C00101
    wherein;
      • ring A is a 5- to 6-membered aromatic or 3- to 6-membered non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, SO, or SO2;
      • wherein said ring A is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
      • wherein any ring has up to 3 substituents selected independently from J; and
      • R9′, R10′, R11, and R11′ are as defined in any of the embodiments herein.
        According to another embodiment for compounds of formula I or formula I-1, the
        Figure US20050119189A1-20050602-C00102
        radical is:
        Figure US20050119189A1-20050602-C00103
        Figure US20050119189A1-20050602-C00104
        Figure US20050119189A1-20050602-C00105
  • According to yet another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00106
    radical is:
    Figure US20050119189A1-20050602-C00107
  • According to another embodiment, the present invention provides a compound of formula IG:
    Figure US20050119189A1-20050602-C00108
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9′, R10′, R11′, R12, z, W. and ring A are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IG-1:
    Figure US20050119189A1-20050602-C00109
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9′, R10′, R11′, R12, R12′, Z, W. X, V, and ring A are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IG or formula IG-1, z is 1.
  • According to another embodiment of compounds of formula IG or formula IG-1, z is 0.
  • According to yet another embodiment for compounds of formula IG or formula IG-1, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00110
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to still another embodiment for compounds of formula IG or formula IG-1, z is 0, w is selected from:
    Figure US20050119189A1-20050602-C00111
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00112
    radical is:
    Figure US20050119189A1-20050602-C00113
    wherein:
      • ring B forms a 3- to a 20-membered carbocyclic or heterocyclic ring system;
      • wherein each ring B is either aromatic or nonaromatic;
      • wherein each heteroatom in the heterocyclic ring system is N, NH, O, SO, or SO2;
      • wherein ring B is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
      • wherein each ring has up to 3 substituents selected independently from J; and
        R9′ and R11′ are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, the
    Figure US20050119189A1-20050602-C00114
    radical is:
    Figure US20050119189A1-20050602-C00115
  • According to yet another embodiment, the present invention provides a compound of formula IH:
    Figure US20050119189A1-20050602-C00116
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9′, R11′, R12, z, W, and ring B are as defined in any of the embodiments herein.
  • According to yet another embodiment, the present invention provides a compound of formula 1H-1:
    Figure US20050119189A1-20050602-C00117
    wherein:
      • R1, R2, R3, R4, R5, R5′, R7, R9′, R11′, R12, R12′, z, X, V, W, and ring B are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IH and formula 1H-1, z is 1.
  • According to another embodiment for compounds of formula IH and formula 1H-1, z is 0.
  • According to yet another embodiment for compounds of formula IH or formula 1H-1, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00118
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IH or formula 1H-1, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00119
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment, W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00120
    wherein in the W, the NR6R6 is selected from —NH—(C1-C6 aliphatic), —NH—(C3-C6 cycloalkyl), —NH—CH(CH3)-aryl, or —NH—CH(CH3)-heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens.
  • According to another embodiment for compounds of formula I or formula I-1, the NR6R6 in the W radical is:
    Figure US20050119189A1-20050602-C00121
  • According to another embodiment for compounds of formula I or formula I-1, the NR6R6 in the W radical is:
    Figure US20050119189A1-20050602-C00122
  • In another embodiment of compounds of formula I or formula I-1, in the W, the NR6R6 is:
    Figure US20050119189A1-20050602-C00123
  • In yet another embodiment for compounds of formula I or formula I-1, in the W, the NR6R6 is:
    Figure US20050119189A1-20050602-C00124
  • According to another embodiment for compounds of formula I or formula I-1, the NR6R6 in the W radical is:
    Figure US20050119189A1-20050602-C00125
  • According to another embodiment in compounds of formula I or formula I-1, the NR6R6 in the W radical is:
    Figure US20050119189A1-20050602-C00126
  • In yet another embodiment for compounds of formula I or formula I-1, in the W, the NR6R6 is:
    Figure US20050119189A1-20050602-C00127
  • According to another embodiment, the present invention provides a compound of formula IJ:
    Figure US20050119189A1-20050602-C00128
    wherein:
      • z, R1, R2, R3, R4, R5, R5′, R6, R7, R9, R9′, R10, R10′, R11, R11′, and R12, are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IJ-1:
    Figure US20050119189A1-20050602-C00129
    wherein:
      • R1, R2, R3, R4, R5, R5′, R6, R7, R9, R9′, R10, R10′, R11, R11′, R11′, R12, z, X, and V are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IJ and formula IJ-1, z is 1.
  • According to another embodiment, W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00130
    wherein R8 is as defined above.
  • According to another embodiment for W in compounds of formula I or formula I-1, each R8 together with the boron atom, is a (C5-C10)-membered heterocyclic ring having no additional heteroatoms other than the boron and the two oxygen atoms. In one embodiment, the heterocyclic ring is:
    Figure US20050119189A1-20050602-C00131
      • wherein R′ is (C1-C6)-aliphatic. In another embodiment, R′ is methyl.
  • According to another embodiment, when W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00132
    wherein R8 is as defined above, then z is 1.
  • According to another embodiment, W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00133
    wherein R6 is as defined in any of the embodiments herein.
  • According to another embodiment, when W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00134
    wherein R6 is as defined in any of the embodiments herein, then z is 1.
  • According to yet another embodiment, W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00135
    wherein R6 is as defined in any of the embodiments herein.
  • According to another embodiment, when W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00136
    wherein R6 is as defined in any of the embodiments herein, then z is 1.
  • According to another embodiment, W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00137
    wherein R6 is as defined in any of the embodiments herein.
  • According to another embodiment, when W in compounds of formula I or formula I-1 is:
    Figure US20050119189A1-20050602-C00138
    wherein R6 is hydrogen, then z is 1.
  • According to another embodiment, the present invention provides a compound of formula Ij:
    Figure US20050119189A1-20050602-C00139
    wherein:
      • R1, R2, R3, R4, R5, R5′, R6, R7, R9, R9′, R10, R10′, R11, R11′, R12′, R12, and z are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula Ij, z is 1.
  • According to another embodiment for compounds of formula Ij, R5, and R5′ are:
    Figure US20050119189A1-20050602-C00140
  • According to another embodiment for compounds of formula Ij, R5, and R5′ are:
    Figure US20050119189A1-20050602-C00141
  • According to another embodiment for compounds of formula I or formula I-1, R5′ is hydrogen and R5 is:
    Figure US20050119189A1-20050602-C00142
  • According to another embodiment for compounds of formula I or formula I-1, R5′ is hydrogen and R5 is:
    Figure US20050119189A1-20050602-C00143
  • According to another embodiment, the present invention provides a compound of formula IK:
    Figure US20050119189A1-20050602-C00144
    wherein:
      • z, R1, R2, R3, R4, R6, R7, R9, R9′, R10, R10′, R11, R11′, and R12, are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IK-1:
    Figure US20050119189A1-20050602-C00145
    wherein:
      • R1, R2, R3, R4, R6, R7, R9, R9′, R10, R10′, R11, R11′, R12′, R12, z, X, and V are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IK or formula IK-1, R1, R2, R3, R4, R6, R7, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X, and V are as defined in any of the embodiments herein, z is 1, and NR6R6 is:
    Figure US20050119189A1-20050602-C00146
  • According to another embodiment for compounds of formula IK or formula IK-1, R1, R2, R3, R4, R6, R7, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X, and V are as defined in any of the embodiments herein and z is 1.
  • According to another embodiment, the present invention provides a compound of formula IK-2:
    Figure US20050119189A1-20050602-C00147
    wherein:
      • R1, R2, R3, R4, R7, R9, R9′, R10, R10′, R11, R11′, R12′, R12, z, X, V, and W are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IK-2, z is 1, W is selected from:
    Figure US20050119189A1-20050602-C00148
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IK-2, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00149
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, R5′ and R5 are:
    Figure US20050119189A1-20050602-C00150
  • According to another embodiment for compounds of formula I or formula I-1, R7 if present, and R2, R4, and R12′ are each independently H, methyl, ethyl, or propyl.
  • According to another embodiment for compounds of formula I or formula I-1, R7 if present, and R2 and R4 are each H.
  • According to another embodiment, the present invention provides a compound of formula IL:
    Figure US20050119189A1-20050602-C00151
    wherein:
      • z, R1, R3, R6, R9, R9′, R10, R10′, R11, R11′, and R12 are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IL-1:
    Figure US20050119189A1-20050602-C00152
    wherein:
      • R1, R3, R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, z, X, and V are as defined in any of the embodiments herein.
  • According to one embodiment for compounds of formula IL or formula IL-1, R1, R3, R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, z, X, and V are as defined in any of the embodiments herein, and NR6R6 is:
    Figure US20050119189A1-20050602-C00153
  • According to another embodiment for compounds of formula IL or formula IL-1, z is one, R1, R3, R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X, and V are as defined in any of the embodiments herein, and NR6R6 is:
    Figure US20050119189A1-20050602-C00154
  • According to another embodiment, the present invention provides a compound of formula IL-2:
    Figure US20050119189A1-20050602-C00155
    wherein:
      • R1, R3, R5, R5′, R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, z, X, V, and W are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IL-2, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00156
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IL-2, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00157
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, R3 is:
    Figure US20050119189A1-20050602-C00158
  • According to another embodiment for compounds of formula I or formula I-1, R3 is:
    Figure US20050119189A1-20050602-C00159
  • According to yet another embodiment for compounds of formula I or formula I-1, R3 is:
    Figure US20050119189A1-20050602-C00160
  • According to another embodiment, the present invention provides a compound of formula IM:
    Figure US20050119189A1-20050602-C00161
    wherein:
      • z is 1, and R1, R6, R9, R9′, R10, R10′, R11, R11′, and R12 are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IM-1:
    Figure US20050119189A1-20050602-C00162
    wherein:
      • z is 1, and R1, R6, R9, R9′, R10, R10′, R11, R11′, R12, R12′, X, and V are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IM-2:
    Figure US20050119189A1-20050602-C00163
    wherein:
      • R1, R5, R5′, R6, R9, R9′, R10, R10′, R11, R11′, R12, R12′, z, X, V, and W are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IM-3:
    Figure US20050119189A1-20050602-C00164
    wherein:
      • R1, R2, R4, R5, R5′, R6, R7, R9, R9′, R10, R10′, R11, R11′, R12, R12′, z, X, V, and W are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IM-2 or formula IM-3, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00165
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IM-2 or formula IM-3, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00166
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, R1 is:
    Figure US20050119189A1-20050602-C00167
  • According to another embodiment for compounds of formula I or formula I-1, R1 is:
    Figure US20050119189A1-20050602-C00168
  • In yet another embodiment for compounds of formula I or formula I-1, R1 is cyclohexyl.
  • According to another embodiment, the present invention provides a compound of formula IN:
    Figure US20050119189A1-20050602-C00169
    wherein:
      • R6, R9, R9′, R10, R10′, R11, R11′, and R12 are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IN-1:
    Figure US20050119189A1-20050602-C00170
    wherein:
      • R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X and V are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IN, and formula IN-1, R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X and V are as defined in any of the embodiments herein, and NR6R6 is:
    Figure US20050119189A1-20050602-C00171
  • According to another embodiment, the present invention provides a compound of formula IN-2:
    Figure US20050119189A1-20050602-C00172
    wherein:
      • R3, R5, R5′, R6, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X V, and W are as defined in any of the embodiments herein.
  • According to another embodiment, the present invention provides a compound of formula IN-3:
    Figure US20050119189A1-20050602-C00173
    wherein:
      • R2, R3, R4, R5, R5′, R6, R7, R9, R9′, R10, R10′, R11, R11′, R12′, R12, X, V, and W are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IN-2 or formula IN-3, z is one, W is selected from:
    Figure US20050119189A1-20050602-C00174
    and R6 and R8 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula IN-2 or formula IN-3, z is 0, W is selected from:
    Figure US20050119189A1-20050602-C00175
    and R14 and R15 are as defined in any of the embodiments herein.
  • According to another embodiment for compounds of formula I or formula I-1, optional J substituents on any substitutable nitrogen are selected from —R′, —N(R′)2, —N(R′)SO2R′, —SO2R′, —SO2N(R′)2, —C(O)R′, —C(O)OR′, —C(O)C(O)R′, —C(O)C(O)N(R′)2, —C(O)CH2C(O)R′, —C(═NH)N(R′)2, or —C(O)N(R′)2.
  • According to another embodiment for compounds of formula I or formula I-1, no carbon atoms of R1, R3, R5, and R5′ are replaced with N. NH, O, or S. In other embodiments of compounds of formula I or I-1, these R1, R3, R5, and R5′ groups have no J substituents.
  • According to another embodiment for compounds of formula I, the compound is:
    Figure US20050119189A1-20050602-C00176
  • The compounds of this invention may contain one or more asymmetric carbon atoms and thus may occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. All such isomeric forms of these compounds are expressly included in the present invention. Each stereogenic carbon may be of the R or S configuration.
  • In one embodiment, the compounds of this invention have the structure and stereochemistry depicted in compounds 1-12.
  • Any of the embodiments recited herein, including those embodiments in the above species, may define formula I or formula I-1 individually or be combined to produce an embodiment of this invention.
  • Abbreviations which are used in the schemes, preparations and the examples that follow are:
    • THF: tetrahydrofuran
    • DMF: N,N,-dimethylformamide
    • EtOAc: ethyl acetate
    • AcOH: acetic acid
    • NMM: N-methylmorpholine
    • NMP: N-methylpyyrolidinone
    • EtOH: ethanol
    • t-BuOH: tert-butanol
    • Et2O: diethyl ether
    • DMSO: dimethyl sulfoxide
    • DCCA: dichloroacetic acid
    • DIEA: diisopropylethylamine
    • MeCN: acetonitrile
    • TFA: trifluoroacetic acid
    • DBU: 1,8-diazabicyclo[5.4.0]undec-7-ene
    • DEAD: diethyl azodicarboxylate
    • HOBt: 1-hydroxybenzotriazole hydrate
    • HOAt: 1-hydroxy-7-azabenzotriazole
    • EDC: 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
    • Boc: tert-butyloxycarbonyl
    • Boc2O: di-tert-butyldicarbonate
    • Cbz: benzyloxycarbonyl
    • Cbz-Cl: benzyl chloroformate
    • Fmoc: 9-fluorenyl methyloxycarbonyl
    • Chg: cyclohexylglycine
    • t-BG: tert-butylglycine
    • mCBPA: 3-chloroperoxybenzoic acid
    • DAST: (diethylamino)sulfur trifluoride
    • TEMPO: 2,2,6,6-tetramethyl-1-piperidinyloxy, free radical
    • PyBOP: tris(pyrrolidino)bromophosphonium hexafluorophosphate
    • TBTU or HATU: 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
    • DMAP: 4-dimethylaminopyridine
    • AIBN: 2,2′-azobisisobutyronitrile
    • DMEM: Dulbecco's minimal essential media
    • PBS: phosphate-buffered saline
    • rt or RT: room temperature
    • ON: overnight
    • ND: not determined
    • MS: mass spectrometry
    • LC: liquid chromatography
      General Synthetic Methodology:
  • The compounds of this invention may be prepared in general by methods known to those skilled in the art. Schemes 1-16 below illustrate synthetic routes to the compounds of the present invention. Other equivalent schemes, which will be readily apparent to the ordinary skilled organic chemist, may alternatively be used to synthesize various portions of the molecule as illustrated by the general schemes below, and the preparative examples that follow.
    Figure US20050119189A1-20050602-C00177
    Figure US20050119189A1-20050602-C00178
  • Scheme 1 above provides a general route for the preparation of compounds of formula I, II, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL, IN, and IN wherein X-V is —C(O)C(O), W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and R1, R3, R5, R5′, R9, R9′, R10, R10′, R11, R11′, R12, and R12′ are as described in any of the embodiments herein. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediates 15, 17, 19, and 22. Additionally, it will be recognized that the commercially available Cbz protected amino acids represented by, for instance, Cbz-P3-OH, may alternatively be substituted with the commercial t-Boc protected amino acids. Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art. Likewise the oxidation of intermediate 22 to compounds of formula II may be accomplished using other suitable conditions known to the skilled artisan.
    Figure US20050119189A1-20050602-C00179
  • Scheme 2 above provides a general route for the preparation of compounds of formula 26. Therein, commercially available amine 23 and sulfonyl chloride 24 are condensed and then hydrolyzed under basic conditions to provide intermediate acid 26. Alternatively, the skilled practitioner will recognize that other suitable reagents may be used to prepare intermediate 26.
    Figure US20050119189A1-20050602-C00180
  • Scheme 3 above provides a general route for the preparation of compounds of formula III and formula I. Therein, coupling of the acid 26 and amine 20 to give amide intermediate 27 may be accomplished using the conditions indicated or coupling reagents known to one of skill in the art. Subsequent oxidation of keto alcohol 27 with Dess Martin periodinane, or other oxidation conditions known to those skilled in the art, affords compounds of formula III or formula I, wherein X-V is —C(O)S(O)1-2, W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and R1, R3, R5, R5′, R9, R9′, R10, R10′, R11, R11′, R12, and R12′ are as described in any of the embodiments herein.
    Figure US20050119189A1-20050602-C00181
  • Scheme 4 above provides a general route for the preparation of compounds of formula VI and formula I. Therein, compound 28 is prepared according to the methods described in Kessler et al., J. Med. Chem., pp. 1918-1930 (2003). Addition of the Fmoc-oxadiazolone in an appropriate solvent gives semi-carbazide 29. Deprotection of the Fmoc group with piperidine in N-methylpyrrolidinone followed by oxidation with Dess Martin periodinane gives compounds of formula IV. It will be appreciated by those skilled in the art that other known conditions can be used to accomplish the oxidation of compounds 29 to compounds of formula I and IV.
    Figure US20050119189A1-20050602-C00182
  • Scheme 5 above provides a general route for the preparation of compounds of formula V and formula I. Therein, commercially available amino acid ester 30 is converted to the corresponding N-chlorosulfonyl ester 31 according to the procedure described by Kempf, D. J. et al., J. Med. Chem., pp. 320-330 (1993). Coupling of 31 with commercially available hydrazine 32 followed by hydrolysis yields acid 34. Coupling of the acid 34 and amine 18 to give amide intermediate 35 may be accomplished using the conditions indicated or coupling reagents known to one of skill in the art. Subsequent oxidation of 35 with Dess Martin periodinane, or other suitable conditions known to those skilled in the art, affords compounds of formula V and formula I.
    Figure US20050119189A1-20050602-C00183
  • Scheme 6 above provides a general route for the preparation of compounds of formula I and formula VI, wherein X-V is —S(O)1-2C(O)—, W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and R1, R3, R5, R5′, R9, R9′, R10, R10′, R11, R11′, R12, and R12′ are as described in any of the embodiments herein. Chloroester 37 is prepared according to the methods described in J. Org. Chem., pp. 2624-2629 (1979). Coupling of commercially available amino t-butyl ester 36 with chloride 37 gives sulfonamide 38. Basic hydrolysis of mixed ester 38 followed by coupling with commercially available amine 39 affords intermediate ester 40. Oxidation with one equivalent of mCBPA affords sulfoxide 41, wherein X is —S(O)1—. Alternatively, oxidation with two equivalents of mCBPA affords sulfone 41, wherein X is —S(O)2—. Acidic hydrolysis of t-butyl ester 40 yields acid 41, which is coupled to amine 18 (described previously in Scheme 1) to give keto alcohol 42. Finally, oxidation of 42 with Dess Martin periodinane or other suitable conditions know in the art gives compounds of formula VI.
    Figure US20050119189A1-20050602-C00184
    Figure US20050119189A1-20050602-C00185
  • Scheme 7 above provides a general route for the preparation of compounds of formula IB-1, formula IB, and formula IC, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and n, Z, Z′, R1, R3, R5, R5′, R9, R9′, R10, R10′, R11, R11′, R12, and R12′ are as described in any of the embodiments herein. As would be recognized by skilled practitioners, other suitable and commercially available coupling reagents may be used to prepare intermediates 47, 49, 51, and 53. Additionally, it will be recognized that the commercially available Boc protected amino acids represented by, for instance, Boc-P3-OH, may alternatively be substituted with the commercial CBz protected amino acids. Suitable deprotection conditions to remove the Cbz protecting groups are known to those skilled in the art. Likewise the oxidation of intermediate 53 to compounds of formula IB-1 may be accomplished using other suitable conditions known to the skilled artisan.
    Figure US20050119189A1-20050602-C00186
    Figure US20050119189A1-20050602-C00187
  • Scheme 8 above provides a general route for the preparation of compounds of formula ID-1 and formula ID, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and R1, R3, R5, R5′, R6, R12, and R12′ are as described in any of the embodiments herein. As would be recognized by any skilled practitioner, other suitable and commercially available coupling reagents may be used to prepare intermediates 56, 58, 60, and 62. Additionally, it will be recognized that the commercially available Boc protected amino acids represented by, for instance, Boc-P3-OH, may alternatively be substituted with the commercial CBz protected amino acids. Suitable deprotection conditions to remove the Cbz protecting groups are known to those skilled in the art. Likewise, the oxidation of intermediate 62 to compounds of formula ID-1 may be accomplished using other suitable conditions known to the skilled artisan.
    Figure US20050119189A1-20050602-C00188
    Figure US20050119189A1-20050602-C00189
  • Scheme 9 above provides a general route for the preparation of compounds of formula IE-1 and formula IE, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R6)2, R2R4, and R7 are H, and R′, R1, R3, R5, R5′, R6, R12 and R12′ are as described in any of the embodiments herein. The steps used in scheme 9 could be modified by, for example, using different reagents or carrying out the reactions in a different order. As would be recognized by any skilled practitioner, other suitable and commercially available coupling reagents may be used to prepare intermediates 66, 67, 69, and 70. Additionally, it will be recognized that the commercially available Cbz protected amino acids represented by, for instance, Cbz-P3-OH, may alternatively be substituted with the commercial t-Boc protected amino acids. Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art. Likewise, the oxidation of intermediate 70 to compounds of formula IE-1 may be accomplished using other suitable conditions known to the skilled artisan.
    Figure US20050119189A1-20050602-C00190
  • Scheme 10 above, depicts an alternative approach to preparing compounds of formulae IE-1 and IE of this invention wherein, X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and R′, R1, R3, R5, R5′, R6, R12, and R12′ are as described in any of the embodiments herein. In this approach, a 4-hydroxyproline derivative 71 is reacted with a commercially available R′-halide (such an aryl chloride), represented by R′—X, in the presence of a suitable base (such as potassium t-butoxide) to provide a compound 72. As would be appreciated by any skilled practitioner, the compound 72 then may be carried on to compounds of formula IE-1 by routine methods. Additionally, other suitable and commercially available coupling reagents may be used to prepare intermediates 74, 75, 76, and 77. Furthermore, it will be recognized that the commercially available Boc protected amino acids represented by, for instance, Boc-P3-OH, may alternatively be substituted with the commercial CBz protected amino acids. Suitable deprotection conditions to remove the Cbz protecting groups are known to those skilled in the art. Likewise, the oxidation of intermediate 77 to compounds of formula IE-1 may be accomplished using other suitable conditions known to the skilled artisan.
    Figure US20050119189A1-20050602-C00191
  • Scheme 11 above provides a general route for the preparation of compounds of formula IF-1 and formula IF, wherein X-V is —C(O)C(O)—, W is —C(O)C(O)—N(R6)2, R2, R4, and R7 are H, and ring A, R1, R3, R5, R5′, R6, R12, and R12′ are as described in any of the embodiments herein. The steps used in scheme 11 could be modified by, for example, using different reagents or carrying out the reactions in a different order. As would be recognized by any skilled practitioner, other suitable and commercially available coupling reagents may be used to prepare intermediates 79, 80, 81, and 82. Additionally, it will be recognized that the commercially available Cbz protected amino acids represented by, for instance, Cbz-P3-OH, may alternatively be substituted with the commercial t-Boc protected amino acids. Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art. Likewise, the oxidation of intermediate 82 to compounds of formula IF-1 may be accomplished using other suitable conditions known to the skilled artisan.
    Figure US20050119189A1-20050602-C00192
  • Scheme 12 above provides a synthetic route for the preparation of compound 84. Scheme 12 could be modified using techniques known to skilled practitioners to arrive at compound 84. Additionally, other commercially available oxalamide esters may be converted into the corresponding acids by a route analogous to that described above.
    Figure US20050119189A1-20050602-C00193
  • Scheme 13 provides a synthetic route for the preparation of non-commercially available oxalamide esters or oxalamide acids of interest. Scheme 13 may be modified using techniques known to skilled practitioners to arrive at compounds represented by formula 88.
    Figure US20050119189A1-20050602-C00194
    Figure US20050119189A1-20050602-C00195
  • Scheme 14 above provides a synthetic route for the preparation of compound 1 from 89 (BOC-protected octahydro-indole-2-carboxylic acid). Intermediate 89 may be prepared from commercially available octahydro-indole-2-carboxylic acid (Bachem) according to the procedure described in PCT publication No. WO 03/087092 (the entire of contents of which is hereby incorporated by reference) and references cited therein. Scheme 14 could be modified using techniques known to skilled practitioners to arrive at compound 1. The experimental procedures to prepare compound 1 are further exemplified below in Example 2.
    Figure US20050119189A1-20050602-C00196
  • Scheme 15 above provides a synthetic route for the preparation of Cbz-protected azabicyclo[2.2.1]heptane-3-carboxylic acid, compound 99 and the corresponding t-butyl ester, compound 100. The free acid 99 may be further elaborated by the route defined in scheme 1 above to prepare compounds of formulae I and IH. Alternatively, the t-butyl ester 100 may be further elaborated by a modification of schemes 9 or 10 above to give compounds of formulae I and IH.
    Figure US20050119189A1-20050602-C00197
  • Scheme 16 above provides a general route for the preparation of compounds of formula IP and formula I-1, wherein R5 is H, R5′ is n-propyl, W is —C(O)C(O)—NH—C(R14)—C(O)—NH—C(R15)—Y, R2, R4, and R7 are H, and ring A, X, V, R1, R3, R5, R5′, R6, R9, R9′, R10, R10′, R11, R11′, R14, R15, Y, z, R12, and R12′ are as described in any of the embodiments herein. The steps used in scheme 16 could be modified by, for example, using different reagents or carrying out the reactions in a different order. As would be recognized by any skilled practitioner, other suitable and commercially available coupling reagents may be used to prepare intermediates 103, 106, and 108. Additionally, it will be recognized that the commercially available Cbz protected amino acids represented by, for instance, Cbz-R14—COOH, may alternatively be substituted with the commercial t-Boc protected amino acids. Suitable deprotection conditions to remove the Boc protecting groups are known to those skilled in the art. Likewise, the oxidation of intermediate 108 to compounds of formula IP may be accomplished using other suitable conditions known to the skilled artisan. Intermediate acid 105 was prepared according to the procedure described by Harbeson, S. et al., J. Med. Chem., Vol. 37, No. 18, pp. 2918-2929 (1994).
  • The preparation of various other optionally substituted multicyclic azaheterocyclyl intermediates to prepare compounds of formulae I and IG via schemes 1, 9 or 10 above, may be accomplished by the methods described in PCT publication No. WO 02/18369 (the entire of contents of which is hereby incorporated by reference) and references cited therein.
  • Various 3, 4, and 5-substituted proline analogues may either be purchased commercially or prepared according to known literature procedures. For instance, for compounds of formula I wherein R9′ is (C1-C12)-aliphatic-, the starting 3-substituted proline analogues may be prepared according to the method of Holladay, M. W. et al., J. Med. Chem., 34, pp. 457-461 (1991). For compounds of formula I wherein either R9′, R10′, or R11′ are cyclohexyl and R9, R10, or R11 are hydrogen, the cyclohexyl proline intermediates may be prepared by platinum oxide reduction of the commercially available phenyl substituted proline analogues. Such reduction conditions are well known to those skilled in the art. For compounds of formula I wherein R9′ is (C1-C12)-aliphatic- and R10′ is (C1-C12)-aliphatic-, the starting 3,4-disubstituted proline analogues may be prepared according to the method of Kanamasa, S. et al., J. Org. Chem, 56, pp. 2875-2883 (1991). In each of the syntheses involving 3, 4, or 5-substituted prolines or 3,4-disubstituted prolines, the intermediates may be further elaborated by the routes defined above in schemes 1, 9, or 10 to prepare compounds of formula I.
  • Accordingly, one embodiment of this invention provides a process for preparing a compound of formula I, as defined in any of the embodiments herein, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII to provide a compound of formula IX:
    Figure US20050119189A1-20050602-C00198
    wherein:
    • R17 is an amine protecting group, a P3-residue of an HCV protease inhibitor described herein, or a P4-P3-residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally substituted with an amino-terminal capping group;
    • R16 is a carboxy protecting group or a P1 residue of an HCV protease inhibitor described herein, wherein the P1 residue is optionally substituted with a carboxy terminal protecting group or with W. R′ is as defined in any of the embodiments herein. X is an appropriate leaving group. As would be appreciated by skilled practitioners, an appropriate leaving group may be generated in situ.
  • In an alternative embodiment, the 4-hydroxy group in formula VII may be converted to a leaving group. In such an embodiment, X is a nucleophilic oxygen which reacts with VII to provide IX.
  • As used herein, P1, P3, P4 refer to the residues of an HCV protease inhibitor as defined in the art and as are well known to skilled practitioners.
  • The compound of formula IX may be carried on to a compound of formula I according to the methods described herein.
  • Although certain embodiments are depicted and described below, it will be appreciated that compounds of this invention can be prepared according to the methods described generally above using appropriate starting materials generally available to one of ordinary skill in the art.
  • Another embodiment of this invention provides a pharmaceutical composition comprising a compound of formula I or formula I-1 or pharmaceutically acceptable salts thereof. According to another embodiment, the compound of formula I or formula I-1 is present in an amount effective to decrease the viral load in a sample or in a patient, wherein said virus encodes a serine protease necessary for the viral life cycle, and a pharmaceutically acceptable carrier.
  • If pharmaceutically acceptable salts of the compounds of this invention are utilized in these compositions, those salts are preferably derived from inorganic or organic acids and bases. Included among such acid salts are the following: acetate, adipate, alginate, aspartate, benzoate, benzene sulfonate, bisulfate, butyrate, citrate, camphorate, camphor sulfonate, cyclopentane-propionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, 3-phenyl-propionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate and undecanoate. Base salts include ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, N-methyl-D-glucamine, and salts with amino acids such as arginine, lysine, and so forth.
  • Also, the basic nitrogen-containing groups may be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates, such as dimethyl, diethyl, dibutyl and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides, such as benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • The compounds utilized in the compositions and methods of this invention may also be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • According to another embodiment, the compositions of this invention are formulated for pharmaceutical administration to a mammal. In one embodiment said mammal is a human being.
  • Such pharmaceutical compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term “parenteral” as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. In another embodiment, the compositions are administered orally or intravenously.
  • Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents which are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.
  • In one embodiment, dosage levels of between about 0.01 and about 100 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease. In another embodiment, dosage levels of between about 0.5 and about 75 mg/kg body weight per day of the protease inhibitor compounds described herein are useful in a monotherapy for the prevention and treatment of antiviral, particularly anti-HCV mediated disease. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A typical preparation will contain from about 5% to about 95% active compound (w/w). In one embodiment, such preparations contain from about 20% to about 80% active compound.
  • When the compositions of this invention comprise a combination of a compound of formula I or formula I-1 and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 10 to 100% of the dosage normally administered in a monotherapy regimen. In another embodiment, the additional agent should be present at dosage levels of between about 10 to 80% of the dosage normally administered in a monotherapy regimen.
  • The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers that are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.
  • Alternatively, the pharmaceutical compositions of this invention may be administered in the form of suppositories for rectal administration. These may be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.
  • The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.
  • Topical application for the lower intestinal tract may be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.
  • For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions may be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
  • For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with our without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.
  • The pharmaceutical compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.
  • In one embodiment, the pharmaceutical compositions are formulated for oral administration.
  • In another embodiment, the compositions of this invention additionally comprise another anti-viral agent, preferably an anti-HCV agent. Such anti-viral agents include, but are not limited to, immunomodulatory agents, such as α-, β-, and γ-interferons, pegylated derivatized interferon-α compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., compounds of U.S. Pat. Nos. 5,807,876, 6,498,178, 6,344,465, 6,054,472, WO 97/40028, WO 98/40381, WO 00/56331, and mycophenolic acid and derivatives thereof, and including, but not limited to VX-497, VX-148, and/or VX-944); or combinations of any of the above. See also W. Markland et al., Antimicrobial & Antiviral Chemotherapy, 44, p. 859 (2000) and U.S. Pat. No. 6,541,496.
    Figure US20050119189A1-20050602-C00199
  • The following definitions are used herein (with trademarks referring to products available as of this application's filing date).
  • “Peg-Intron” means PEG-Intron®, peginteferon alfa-2b, available from Schering Corporation, Kenilworth, N.J.;
      • “Intron” means Intron-A®, interferon alfa-2b available from Schering Corporation, Kenilworth, N.J.;
      • “ribavirin” means ribavirin (1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide, available from ICN Pharmaceuticals, Inc., Costa Mesa, Calif.; described in the Merck Index, entry 8365, Twelfth Edition; also available as Rebetol® from Schering Corporation, Kenilworth, N.J., or as Copegus® from Hoffmann-La Roche, Nutley, N.J.;
      • “Pagasys” means Pegasys®, peginterferon alfa-2a available Hoffmann-La Roche, Nutley, N.J.;
      • “Roferon” mean Roferon®, recombinant interferon alfa-2a available from Hoffmann-La Roche, Nutley, N.J.;
      • “Berefor” means Berefor®, interferon alfa 2 available from Boehringer Ingelheim Pharmaceutical, Inc., Ridgefield, Conn.;
      • Sumiferon®, a purified blend of natural alpha interferons such as Sumiferon available from Sumitomo, Japan;
      • Wellferon®, interferon alpha n1 available from Glaxo_Wellcome LTd., Great Britain;
      • Alferon®, a mixture of natural alpha interferons made by Interferon Sciences, and available from Purdue Frederick Co., CT;
  • The term “interferon” as used herein means a member of a family of highly homologous species-specific proteins that inhibit viral replication and cellular proliferation, and modulate immune response, such as interferon alpha, interferon beta, or interferon gamma. The Merck Index, entry 5015, Twelfth Edition.
  • According to one embodiment of the present invention, the interferon is α-interferon. According to another embodiment, a therapeutic combination of the present invention utilizes natural alpha interferon 2a. Or, the therapeutic combination of the present invention utilizes natural alpha interferon 2b. In another embodiment, the therapeutic combination of the present invention utilizes recombinant alpha interferon 2a or 2b. In yet another embodiment, the interferon is pegylated alpha interferon 2a or 2b. Interferons suitable for the present invention include:
      • (a) Intron (interferon-alpha 2B, Schering Plough),
      • (b) Peg-Intron,
      • (c) Pegasys,
      • (d) Roferon,
      • (e) Berofor,
      • (f) Sumiferon,
      • (g) Wellferon,
      • (h) consensus alpha interferon available from Amgen, Inc., Newbury Park, Calif.,
      • (i) Alferon;
      • (j) Viraferon®;
      • (k) Infergen®.
  • As is recognized by skilled practitioners, a protease inhibitor would be preferably administered orally. Interferon is not typically administered orally. Nevertheless, nothing herein limits the methods or combinations of this invention to any specific dosage forms or regime. Thus, each component of a combination according to this invention may be administered separately, together, or in any combination thereof.
  • In one embodiment, the protease inhibitor and interferon are administered in separate dosage forms. In one embodiment, any additional agent is administered as part of a single dosage form with the protease inhibitor or as a separate dosage form. As this invention involves a combination of compounds, the specific amounts of each compound may be dependent on the specific amounts of each other compound in the combination. As recognized by skilled practitioners, dosages of interferon are typically measured in IU (e.g., about 4 million IU to about 12 million IU).
  • Accordingly, agents (whether acting as an immunomodulatory agent or otherwise) that may be used in combination with a compound of this invention include, but are not limited to, interferon-alph 2B (Intron A, Schering Plough); Rebatron (Schering Plough, Inteferon-alpha 2B+Ribavirin); pegylated interferon alpha (Reddy, K. R. et al. “Efficacy and Safety of Pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C (Hepatology, 33, pp. 433-438 (2001); consensus interferon (Kao, J. H., et al., “Efficacy of Consensus Interferon in the Treatement of Chronic Hepatitis” J. Gastroenterol. Hepatol. 15, pp. 1418-1423 (2000), interferon-alpha 2A (Roferon A; Roche), lymphoblastoid or “natural” interferon; interferon tau (Clayette, P. et al., “IFN-tau, A New Interferon Type I with Antiretroviral activity” Pathol. Biol. (Paris) 47, pp. 553-559 (1999); interleukin 2 (Davis, G. L. et al., “Future Options for the Management of Hepatitis C.” Seminars in Liver Disease, 19, pp. 103-112 (1999); Interleukin 6 (Davis et al. “Future Options for the Management of Hepatitis C.” Seminars in Liver Disease 19, pp. 103-112 (1999); interleukin 12 (Davis, G. L. et al., “Future Options for the Management of Hepatitis C.” Seminars in Liver Disease, 19, pp. 103-112 (1999); Ribavirin; and compounds that enhance the development of type 1 helper T cell response (Davis et al., “Future Options for the Management of Hepatitis C.” Seminars in Liver Disease, 19, pp. 103-112 (1999). Interferons may ameliorate viral infections by exerting direct antiviral effects and/or by modifying the immune response to infection. The antiviral effects of interferons are often mediated through inhibition of viral penetration or uncoating, synthesis of viral RNA, translation of viral proteins, and/or viral assembly and release.
  • Compounds that stimulate the synthesis of interferon in cells (Tazulakhova, E. B. et al., “Russian Experience in Screening, analysis, and Clinical Application of Novel Interferon Inducers” J. Interferon Cytokine Res., 21 pp. 65-73) include, but are not limited to, double stranded RNA, alone or in combination with tobramycin, and Imiquimod (3M Pharmaceuticals; Sauder, D. N. “Immunomodulatory and Pharmacologic Properties of Imiquimod” J. Am. Acad. Dermatol., 43 pp. S6-11 (2000).
  • Other non-immunomodulatory or immunomodulatory compounds may be used in combination with a compound of this invention including, but not limited to, those specified in WO 02/18369, which is incorporated herein by reference (see, e.g., page 273, lines 9-22 and page 274, line 4 to page 276, line 11).
  • This invention may also involve administering a cytochrome P450 monooxygenase inhibitor. CYP inhibitors may be useful in increasing liver concentrations and/or increasing blood levels of compounds that are inhibited by CYP.
  • If an embodiment of this invention involves a CYP inhibitor, any CYP inhibitor that improves the pharmacokinetics of the relevant NS3/4A protease may be used in a method of this invention. These CYP inhibitors include, but are not limited to, ritonavir (WO 94/14436), ketoconazole, troleandomycin, 4-methylpyrazole, cyclosporin, clomethiazole, cimetidine, itraconazole, fluconazole, miconazole, fluvoxamine, fluoxetine, nefazodone, sertraline, indinavir, nelfinavir, amprenavir, fosamprenavir, saquinavir, lopinavir, delavirdine, erythromycin, VX-944, and VX-497. Preferred CYP inhibitors include ritonavir, ketoconazole, troleandomycin, 4-methylpyrazole, cyclosporin, and clomethiazole. For preferred dosage forms of ritonavir, see U.S. Pat. No. 6,037,157, and the documents cited therein: U.S. Pat. No. 5,484,801, U.S. application Ser. No. 08/402,690, and International Applications WO 95/07696 and WO 95/09614).
  • Methods for measuring the ability of a compound to inhibit cytochrome P50 monooxygenase activity are known (see U.S. Pat. No. 6,037,157 and Yun, et al. Drug Metabolism & Disposition, vol. 21, pp. 403-407 (1993).
  • Upon improvement of a patient's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
  • It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of active ingredients will also depend upon the particular described compound and the presence or absence and the nature of the additional anti-viral agent in the composition.
  • According to another embodiment, the invention provides a method for treating a patient infected with a virus characterized by a virally encoded serine protease that is necessary for the life cycle of the virus by administering to said patient a pharmaceutically acceptable composition of this invention. In another embodiment the methods of this invention are used to treat a patient suffering from a HCV infection. Such treatment may completely eradicate the viral infection or reduce the severity thereof. In one embodiment, the patient is a human being.
  • In an alternate embodiment, the methods of this invention additionally comprise the step of administering to said patient an anti-viral agent preferably an anti-HCV agent. Such anti-viral agents include, but are not limited to, immunomodulatory agents, such as α-, β-, and γ-interferons, pegylated derivatized interferon-α compounds, and thymosin; other anti-viral agents, such as ribavirin, amantadine, and telbivudine; other inhibitors of hepatitis C proteases (NS2-NS3 inhibitors and NS3-NS4A inhibitors); inhibitors of other targets in the HCV life cycle, including helicase and polymerase inhibitors; inhibitors of internal ribosome entry; broad-spectrum viral inhibitors, such as IMPDH inhibitors (e.g., VX-497 and other IMPDH inhibitors disclosed in U.S. Pat. Nos. 5,807,876 and 6,498,178, mycophenolic acid and derivatives thereof); inhibitors of cytochrome P-450, such as ritonavir, or combinations of any of the above.
  • Such additional agent may be administered to said patient as part of a single dosage form comprising both a compound of this invention and an additional anti-viral agent. Alternatively the additional agent may be administered separately from the compound of this invention, as part of a multiple dosage form, wherein said additional agent is administered prior to, together with or following a composition comprising a compound of this invention.
  • In yet another embodiment the present invention provides a method of pre-treating a biological substance intended for administration to a patient comprising the step of contacting said biological substance with a pharmaceutically acceptable composition comprising a compound of this invention. Such biological substances include, but are not limited to, blood and components thereof such as plasma, platelets, subpopulations of blood cells and the like; organs such as kidney, liver, heart, lung, etc; sperm and ova; bone marrow and components thereof, and other fluids to be infused into a patient such as saline, dextrose, etc.
  • According to another embodiment the invention provides methods of treating materials that may potentially come into contact with a virus characterized by a virally encoded serine protease necessary for its life cycle. This method comprises the step of contacting said material with a compound according to the invention. Such materials include, but are not limited to, surgical instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); laboratory instruments and garments (e.g. clothes, gloves, aprons, gowns, masks, eyeglasses, footwear, etc.); blood collection apparatuses and materials; and invasive devices, such as shunts, stents, etc.
  • In another embodiment, the compounds of this invention may be used as laboratory tools to aid in the isolation of a virally encoded serine protease. This method comprises the steps of providing a compound of this invention attached to a solid support; contacting said solid support with a sample containing a viral serine protease under conditions that cause said protease to bind to said solid support; and eluting said serine protease from said solid support. Preferably, the viral serine protease isolated by this method is HCV NS3-NS4A protease.
  • In order that this invention be more fully understood, the following preparative and testing examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.
    • EXAMPLES
  • 1H-NMR spectra were recorded at 500 MHz using a Bruker AMX 500 instrument. Mass spec. samples were analyzed on a MicroMass ZQ or Quattro II mass spectrometer operated in single MS mode with electrospray ionization. Samples were introduced into the mass spectrometer using flow injection (FIA) or chromatography. Mobile phase for all mass spec. analysis consisted of acetonitrile-water mixtures with 0.2% formic acid as a modifier.
  • As used herein, the term “Rt(min)” refers to the HPLC retention time, in minutes, associated with the compound. The HPLC retention times listed were either obtained from the mass spec. data or using the following method:
    • Instrument: Hewlett Packard HP-1050;
    • Column: YMC C18 (Cat. No. 326289C46);
    • Gradient/Gradient Time: 10-90% CH3CN/H2O over 9 minutes, then 100% CH3CN for 2 minutes;
    • Flow Rate: 0.8 ml/min;
    • Detector Wavelength: 215 nM and 245 nM.
  • Chemical naming for selected compounds herein was accomplished using the naming program provided by CambridgeSoft Corporations ChemDraw Ultra®, version 7.0.1.
    • Example 1
  • N-Phenyl Oxalamic Acid (84)
  • Ethyl oxanilate 83 (Aldrich, 1.0 g, 1.0 eq) in 12 mL of THF was treated dropwise with a 1N NaOH solution (5.70 mL, 1.1 eq) resulting in a white precipitate. After stirring for 3 hours at RT, 0.5N HCl and ethyl acetate were added, the organic layer separated, washed with 0.5N HCl and brine and then dried over sodium sulfate, filtered, and concentrated to give 712 mg (68%) of N-phenyl oxalamic acid 84 as a white solid with consistent analytical data. FIA M+H=166.0, M−H=163.9; 1H NMR (DMSO-d6) δ 10.70 (s,1H), 7.75 (m,2H), 7.35 (m,2H), 7.15 (m,1H) ppm.
    • Example 2 N-(Cyclohexyl-{1-[2-(1-cyclopropylaminooxalyl-butylcarbamoyl)-octahydro-indole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-N′-phenyl-oxalamide (1)
  • Octahydro-indole-1,2-dicarboxylic acid 1-tert-butyl ester 89 (Bachem, 1.6 g, 1.0 eq) in DMF (20 mL) was treated with PyBOP (3.41 g, 1.1 eq) and NMM (1.97 mL, 3.0 eq). To this was added 3-amino-2-hydroxy-hexanoic acid cyclopropylamide 90 (1.22 g, 1.1 eq, prepared according to the procedure of U. Schoellkogf et al., Justus Liebigs Ann. Chem. GE, pp. 183-202 (1976) and J. Semple et al., Org. Letters, 2, pp. 2769-2772 (2000) and NMM (1.97 mL, 3.0 eq) in DMF (3 mL) and the mixture stirred at rt overnight. The mixture was evaporated in vacuo, diluted with ethyl acetate, the organic phase washed with 0.5N HCl, sodium bicarbonate and brine, then dried over sodium sulfate, filtered and concentrated in vacuo to give 2-[1-cyclopropylcarbamoyl-hydroxy-methyl)-butylcarbamoyl]-octahydro-indole-1-carboxylic acid tert-butyl ester 91 which was used without further purification. 1H NMR (CDCl3) δ 6.92 (bs, 1H), 6.80 (bs, 1H), 3.80-4.20 (m, 3H), 2.75 (m, 1H), 2.25 (m, 1H), 2.10 (m, 1H), 1.90-2.00 (m, 2H), 1.5-1.75 (m, 7H), 1.45 (s, 9H), 1.10-1.40 (m, 5H), 0.90 (m, 3H), 0.75 (m, 2H), 0.50 (m, 2H) ppm.
  • Crude Boc amide 91 was stirred in ethyl acetate (0.5N), treated with anhydrous 2N HCl in EtOAc and the mixture stirred for 2 hours. The mixture was concentrated in vacuo to give octahydro-indole-2-carboxylic acid [1-(cyclopropylcarbamoyl-hydroxy-methyl)butyl]-amide 92 which was used without further purification. 1H NMR (CDCl3) δ 7.10 (bs, 1H), 6.95 (bs, 1H), 4.60 (m, 1H), 4.30 (m, 1H), 3.85 (m, 1H), 2.75 (m, 1H), 2.50 (m, 2H), 2.05 (m, 2H), 1.30-1.80 (m, 12H), 0.90 (m, 3H), 0.80 (m, 2H), 0.60 (m, 2H) ppm.
  • CBz tert-butyl glycine (1.74 g, 1.1 eq), and crude amine 92 (2.01 g, 1.0 eq) in DMF (20 mL) were treated with PyBOP (3.41 g, 1.1 eq) and NMM (3.93 mL, 6.0 eq) and the mixture stirred overnight at room temperature. The reaction mixture was concentrated in vacuo, diluted with EtOAc and the organic layer washed with 0.5N HCl, brine, sodium bicarbonate solution and brine, then dried over sodium sulfate, filtered, and concentrated in vacuo. Purification on Merck silica gel eluting with a gradient (20% EtOAc/Hexanes to 100% EtOAc) afforded 2.295 g (66%) of (1-{2-[1-(cyclopropylcarbamoyl-hydroxy-methyl)-butylcarbamoyl]-octahydro-indole-1-carbonyl}-2,2-dimethyl-propyl)-carbamic acid benzyl ester 93 as an oil with consistent analytical data. LCMS ret time=4.09 min, M+H=585.28, M−H=583.25; 1H NMR (CDCl3) δ 7.32 (m, 5H), 6.99 (d, 1H), 6.85 (m, 1H), 5.42 (d, 1H), 5.02-5.12 (m, 2H), 4.50 (t, 1H), 4.25 (d, 1H), 4.09 (m, 1H), 3.95 (m, 1H), 2.72 (m, 1H), 2.12-2.30 (m, 2H), 1.95 (m, 2H), 1.59-1.81 (m, 6H), 1.50 (m, 2H), 1.22-1.42 (m, 4H), 1.00 (s, 9H), 0.90 (m, 3H), 0.75 (m, 2H), 0.55 (m, 2H) ppm.
  • Amide 93 (1.10 g, 1.0 eq) in EtOH (10 mL) was treated with 10% Pd/C (100 mg) and hydrogen gas was bubbled into the black suspension until starting material was consumed (monitored by TLC). Catalyst was removed by filtration and the filtrate concentrated in vacuo to give 852 mg (100% yield) of 1-(2-amino-3,3-dimethyl-butyryl)-octahydro-indole-2-carboxylic acid [1-(cyclopropylcarbamoyl-hydroxy-methyl)-butyl]-amide 94 as a white solid with consistent NMR data. 1H NMR (CDCl3) δ 4.40 (m, 1H), 4.20 (m, 1H), 4.10 (d, 1H), 3.95 (m, 1H), 2.70 (m, 1H), 2.40 (m, 2H), 2.0 (m, 2H), 1.60-1.80 (m, 6H), 1.50 (m, 2H), 1.30 (m, 3H), 1.20 (m, 1H), 1.00 (s, 9H), 0.90 (m, 3H), 0.75 (m, 2H), 0.55 (m, 2H) ppm.
  • CBz-cyclohexylglycine (Bachem, 747 mg, 1.05 eq) in DMF (5 mL) was treated with PyBOP (1.33 g, 1.05 eq) and NMM (0.8 ml, 3.0 eq). To this was added a solution of amine 94 (1.1 g, 1.0 eq) and NMM (0.8 mL, 3.0 eq) in DMF (20 mL) and the mixture stirred at room temperature for 3 hours. The reaction mixture was concentrated in vacuo, diluted with ethyl acetate, the organic phase washed with 0.5N HCl, brine, saturated sodium bicarbonate solution, and brine, then dried over sodium sulfate, filtered, and concentrated in vacuo. Purification via Merck silica gel eluting with 75% EtOAc/Hexanes afforded 1.18 g (67%) of [cyclohexyl-(1-{2-[1-cyclopropylcarbamoyl-hydroxy-methyl)-butylcarbamoyl]-octahydro-indole-1-carbonyl}-2,2-dimethyl-propylcarbamoyl)methyl]-carbamic acid benzyl ester 95 as a white solid with consistent analytical data. LCMS ret time=3.65, M+H=724.22, M−H=722.20; 1H NMR (CDCl3) δ 7.35 (m, 5H), 7.05 (m, 1H), 6.90 (m, 1H), 6.55 (m, 1H), 5.35 (dd, 1), 5.10 (m, 2H), 4.35-4.55 (m, 1H), 3.95-4.25 (3H), 2.75 (m, 1H), 2.20 (m, 1H), 2.00 (m, 1H), 1.65-1.80 (m, 7H), 1.55 (m, 2H), 1.05-1.45 (m, 7H), 1.00 (s, 9H), 0.85-1.00 (m, 7H), 0.80 (m, 2H), 0.55 (m, 2H) ppm.
  • CBz carbamate 95 (1.76 g, 1.0 eq) in EtOH (12 mL). was treated with 10% Pd/C (175 mg) and hydrogen gas was bubbled through the suspension until starting material was consumed (monitored by TLC). Catalyst was removed by filtration and the filtrate concentrated in vacuo to give 1.43 g (100%) of intermediate oxalamide as a white solid which was used without further purification.
  • Acid 84 (20 mg, 1.4 eq) in CH2Cl2 (1 mL) was treated with PyBOP (53 mg, 1.2 eq) and NMM (0.028 mL, 3.0 eq) and stirred for 5 minutes. To this was added a solution of oxalamide (50 mg, 1.0 eq) and NMM (0.028 mL, 3.0 eq) in CH2Cl2 (1 mL) and the mixture stirred at room temperature overnight. The mixture was diluted with ethyl acetate, the organic phase washed with 0.5N HCl, brine, saturated bicarbonate solution, and brine, then dried over sodium sulfate, filtered and concentrated in vacuo. Purification by preparative HPLC yielded 24 mg (38%) of N-[cyclohexyl-(1-{2-[1-cyclopropylcarbamoyl-hydroxy-methyl)-butylcarbamoyl]-octahydro-indole-1-carbonyl}-2,2-dimethyl-propylcarbamoyl)methyl]-N′-phenyl-oxalamide 96 as a white solid with consistent analytical data. LCMS ret time=4.07, M+H=737.26, M−H=735.22.
  • Oxalamide 96 (24 mg, 1.0 eq) in CH2Cl2 (1 mL) and t-BuOH (41 uL) was treated with Dess Martin periodinane (41 mg, 3.0 eq) and the suspension stirred at room temp. for 3 hours. Sodium thiosulfate was added and the mixture stirred for 15 minutes, then diluted with ethyl acetate, the organic phase washed with sodium bicarbonate solution and brine, then dried over anydrous sodium sulfate and concentrated in vacuo. Purification by preparative HPLC yielded 5.5 mg (23%) of N-(cyclohexyl-{1-[2-(1-cyclopropylaminooxalyl-butylcarbamoyl)-octahydro-indole-1-carbonyl]-2,2-dimethyl-propylcarbamoyl}-N′-phenyl-oxalamide 1 as a white solid with consistent analytical data. LCMS ret time=4.51, M+H=735.23, M−H=733.39.
    • Example 3
  • HCV Replicon Cell Assay Protocol:
  • Cells containing hepatitis C virus (HCV) replicon were maintained in DMEM containing 10% fetal bovine serum (FBS), 0.25 mg per ml of G418, with appropriate supplements (media A).
  • On day 1, replicon cell monolayer was treated with a trypsin:EDTA mixture, removed, and then media A was diluted into a final concentration of 100,000 cells per ml wit. 10,000 cells in 100 ul were plated into each well of a 96-well tissue culture plate, and cultured overnight in a tissue culture incubator at 37° C.
  • On day 2, compounds (in 100% DMSO) were serially diluted into DMEM containing 2% FBS, 0.5% DMSO, with appropriate supplements (media B). The final concentration of DMSO was maintained at 0.5% throughout the dilution series.
  • Media on the replicon cell monolayer was removed, and then media B containing various concentrations of compounds was added. Media B without any compound was added to other wells as no compound controls.
  • Cells were incubated with compound or 0.5% DMSO in media B for 48 hours in a tissue culture incubator at 37° C. At the end of the 48-hour incubation, the media was removed, and the replicon cell monolayer was washed once with PBS and stored at −80° C. prior to RNA extraction.
  • Culture plates with treated replicon cell monolayers were thawed, and a fixed amount of another RNA virus, such as Bovine Viral Diarrhea Virus (BVDV) was added to cells in each well. RNA extraction reagents (such as reagents from RNeasy kits) were added to the cells immediately to avoid degradation of RNA. Total RNA was extracted according the instruction of manufacturer with modification to improve extraction efficiency and consistency. Finally, total cellular RNA, including HCV replicon RNA, was eluted and stored at −80° C. until further processing.
  • A Taqman real-time RT-PCR quantification assay was set up with two sets of specific primers and probe. One was for HCV and the other was for BVDV. Total RNA extractants from treated HCV replicon cells was added to the PCR reactions for quantification of both HCV and BVDV RNA in the same PCR well. Experimental failure was flagged and rejected based on the level of BVDV RNA in each well. The level of HCV RNA in each well was calculated according to a standard curve run in the same PCR plate. The percentage of inhibition or decrease of HCV RNA level due to compound treatment was calculated using the DMSO or no compound control as 0% of inhibition. The IC50 (concentration at which 50% inhibition of HCV RNA level is observed) was calculated from the titration curve of any given compound.
    • Example 4
  • HCV Enzyme Assay Protocol:
  • HPLC Microbore Method for Separation of 5AB Substrate and Products
  • Substrate:
    • NH2-Glu-Asp-Val-Val-(alpha)Abu-Cys-Ser-Met-Ser-Tyr-COOH
  • A stock solution of 20 mM 5AB (or concentration of your choice) was made in DMSO w/0.2M DTT. This was stored in aliquots at −20 C.
  • Buffer: 50 mM HEPES, pH 7.8; 20% glycerol; 100 mM NaCl
  • Total assay volume was 100 μL.
    X1 conc. in
    Reagent (μL) assay
    Buffer 86.5 see above
     5 mM KK4A 0.5  25 μM
    1 M DTT 0.5   5 mM
    DMSO or inhibitor 2.5 2.5% v/v
     50 μM tNS3 0.05  25 nM
    250 μM 5AB 20  25 μM
    (initiate)
  • The buffer, KK4A, DTT, and tNS3 were combined; distributed 78 μL each into wells of 96 well plate. This was incubated at 30 C for ˜5-10 min.
  • 2.5 μL of appropriate concentration of test compound was dissolved in DMSO (DMSO only for control) and added to each well. This was incubated at room temperature for 15 min.
  • Initiated reaction by addition of 20 μL of 250 μM 5AB substrate (25 μM concentration is equivalent or slightly lower than the Km for 5AB).
      • Incubated for 20 min at 30 C.
      • Terminated reaction by addition of 25 μL of 10% TFA
      • Transferred 120 μL aliquots to HPLC vials
  • Separated SMSY product from substrate and KK4A by the following method:
  • Microbore Separation Method:
  • Instrumentation: Agilent 1100
    • Degasser G1322A
    • Binary pump G1312A
    • Autosampler G1313A
    • Column thermostated chamber G1316A
    • Diode array detector G1315A
      Column:
    • Phenomenex Jupiter; 5 micron C18; 300 angstroms; 150×2 mm; P/O 00F-4053-BO
    • Column thermostat: 40 C
    • Injection volume: 100 μL
    • Solvent A=HPLC grade water+0.1% TFA
  • Solvent B=HPLC grade acetonitrile+0.1% TFA
    Time Flow Max
    (min) % B (ml/min) press.
     0  5 0.2 400
    12  60 0.2 400
    13 100 0.2 400
    16 100 0.2 400
    17  5 0.2 400
    • Stop time: 17 min
    • Post-run time: 10 min.
  • Table 1 below depicts Mass Spec., HPLC, Ki and IC50 data for certain compounds of the invention. Compounds with Ki's ranging from 0.25 μM to 1 μM are designated A. Compounds with Ki's ranging from 0.1 μM to 0.25 μM are designated B. Compounds with Ki's below 0.1 μM are designated C. Compounds with IC50's ranging from 0.25 μM to 1 μM are designated A. Compounds with IC50's ranging from 0.1 μM to 0.25 μM are designated B. Compounds with IC50's below 0.1 μM are designated C.
    TABLE 1
    HPLC,
    Compound MS+ Rt (min) Ki IC50
     1 735.2 4.51 B A
     2 749.3 4.54 B A
     3 755.4 4.92 B A
     4 699.3 4.04 B A
     5 701.3 4.15 B A
     6 715.2 4.34 B A
     7 740.2 4.19 B A
     8 741.4 4.88 B A
     9 727.4 4.69 A A
    10 772.3 4.30 B C
    11 822.1 4.80 B C
    12 788.0 4.70 B C
  • Table 2 below depicts proton NMR data for certain compounds of the invention. 1H-NMR spectra were recorded at 500 MHz using a Bruker AMX 500 instrument.
    TABLE 2
    Compound 1H-NMR(500 MHz)
     1 ND
     2 (CDCl3) δ 8.67(bs, 1H), 7.96(d, 1H), 7.2-7.3(m, 5H),
    7.90(d, 1H), 5.30(m, 1H), 4.70(m, 1H), 4.65(d, 1H),
    4.60(t, 1H), 4.45(d, 0.5H), 4.40(d, 0.5H), 4.28(m, 1H),
    4.13(m, 1H), 2.75(m, 1H), 2.35(m, 1H), 2.05(m, 1H),
    1.6-1.9(m, 12H), 1.4-1.5(m, 4H), 1.12-1.39(m, 7H),
    1.05(m, 1H), 0.96(s, 9H), 0.85(m, 5H), 0.55(m, 2H) ppm.
     3 (CDCl3) δ 8.10(bs, 1H), 7.99(d, 1H), 7.87(bs, 1H),
    7.52(d, 1H), 7.09(bs, 1H), 5.35(m, 1H),4.70(m, 2H),
    4.60(t, 1H), 4.20(m, 1H), 3.25(m, 1H), 3.10(m, 1H),
    2.80(m, 1H), 2.4(m, 1H), 2.10(m, 1H), 1.90(m, 3H),
    1.10-1.80(m, 26H),0.97(s, 9H), 0.70-0.80(m, 11H),
    0.6(m, 2H) ppm.
     4 (CDCl3) δ 8.12(bs, 1H), 7.97(d, 1H), 7.71(bs, 1H),
    7.22(d, 1H), 6.99(d, 1H), 5.33(m, 1H), 4.67(d, 1H),
    4.60(t, 1H), 4.50(t, 1H), 4.20(m, 1H), 2.83(m, 1H),
    2.79(m, 1H), 2.40(m, 1H), 2.11(m, 1H), 1.82-2.00(m, 5H),
    1.00-1.80(m, 19H), 0.97(s, 9H), 0.62-0.96(m, 10H),
    0.6(m, 2H) ppm.
     5 (CDCl3) δ 7.92(d, 1H), 7.60(d, 1H), 7.39(d, 1H),
    7.10(bs, 1H), 7.00(d, 1H), 5.35(m, 1H), 4.65(d, 1H),
    4.60(t, 1H), 4.40(t, 1H), 4.20(m, 1H), 4.08(m, 1H),
    2.80(m, 1H), 2.45(m, 1H), 2.15(m, 1H), 1.90(m, 3H),
    1.65-1.83(m, 7H), 1.48-1.60(m, 4H), 1.40(m, 3H),
    1.23(d, 3H), 1.20(d, 3H), 1.18-1.30(m, 4H), 1.10(m, 2H),
    0.97(s, 9H), 0.90(m, 4H), 0.85(m, 2H), 0.62(m, 2H) ppm.
     6 (CDCl3) δ 8.15(bs, 1H), 8.00(d, 1H), 7.90(bs, 1H),
    7.44(d, 1H), 7.03(bs, 1H), 5.35(m, 1H), 4.70(d, 1H),
    4.65(t, 1H), 4.60(t, 1H), 4.20(m, 1H), 3.25(m, 1H),
    3.10(m, 1H), 2.80(m, 1H), 2.40(m, 1H), 2.10(m, 1H),
    1.90(m, 4H), 1.00-1.80(m, 21H), 0.97(s, 9H),
    0.94(d, 3H), 0.93(m, 3H), 0.92(d, 3H), 0.88(d, 2H),
    0.62(m, 2H) ppm.
     7 (CDCl3) δ 8.07(bs, 1H), 7.97(d, 1H), 6.92(d, 1H),
    6.79(s, 1H), 5.22(m, 1H), 4.75(t, 1H), 4.62(d, 1H),
    4.58(m, 1H), 4.05(m, 1H), 2.78(m, 1H), 2.57(m, 1H),
    2.42(s, 3H), 2.40(m, 1H), 1.6-1.92(m, 12H),
    1.15-1.50(m, 9H), 0.97-1.10(m, 4H), 0.96(s, 9H),
    0.82(d, 2H), 0.80(t, 3H), 0.61(m, 2H) ppm.
     8 (CDCl3) δ 7.92(d, 1H), 7.59(d, 1H), 7.50(d, 1H),
    7.18(d, 1H), 7.08(bs, 1H), 5.37(m, 1H), 4.67(d, 1H),
    4.66(m, 1H), 4.41(t, 1H), 4.20(m, 1H), 3.77(m, 1H),
    2.78(m, 1H), 2.4(m, 1H), 2.12(m, 1H), 1.90(m, 5H),
    1.01-1.88(m, 27H), 0.99(s, 9H), 0.92(m, 5H),
    0.85(d, 2H), 0.62(m, 2H) ppm.
     9 (CDCl3) δ 7.90(d, 1H), 7.45(d, 1H), 6.95(d, 1H),
    6.67(d, 1H), 5.31(m, 1H), 4.60(m, 2H), 4.30(t, 1H),
    4.20(m, 1H), 2.80(m, 1H), 2.50(m, 1H), 2.15(m, 1H),
    2.04(m, 2H), 1.80-1.95(m, 4H), 1.02-1.78(m, 26H),
    0.97(s, 9H), 0.92(m, 4H), 0.92(d, 2H), 0.60(m, 2H) ppm.
    10 (CDCl3) δ 8.08(d, 1H), 7.87(d, 2H), 7.58(bs, 1H),
    7.50(dd, 1H), 7.48(bs, 1H), 7.10(bs, 1H), 6.51(d, 1H),
    5.60(m, 1H), 5.39(m, 1H), 4.93(m, 1H), 4.77(d, 1H),
    4.52(t, 1H), 4.11(m, 1H), 4.03(m, 1H), 2.80(m, 2H),
    2.53(m, 1H), 2.30(m, 1H), 1.90(m, 1H), 1.67(m, 5H),
    1.57(m, 1H), 1.49(m, 1H), 1.40(m, 2H), 1.20(m, 2H),
    1.07(m, 1H), 0.95(s, 9H), 0.8-0.95(m, 9H),
    0.65(m, 4H) ppm.
    11 (CDCl3) δ 8.10(d, 1H), 7.83(d, 1H), 7.50(d, 1H),
    7.36(m, 1H), 7.30(m, 7H), 7.00(bs, 1H), 6.53(d, 1H),
    5.59(m, 1H), 5.32(m, 1H), 4.78(m, 1H),4.72(d, 1H),
    4.58(d, 0.6H), 4.57(d, 0.4H), 4.48(m, 1H), 4.41(m, 1H),
    4.09(m, 1H), 3.97(d, 0.6H), 3.96(d, 0.4H), 2.79(m, 1H),
    2.56(m, 1H), 2.25(m, 1H), 1.90(m, 1H), 1.70(m, 5H),
    1.50(m, 2H), 1.36(m, 2H), 1.20(m, 2H), 1.08(m, 1H),
    0.97(s, 9H), 0.8-0.91(m, 7H), 0.6(m, 2H) ppm.
    12 (CDCl3) δ 8.09(d, 1H), 7.83(d, 1H), 7.70(bs, 1H),
    7.50(m, 2H), 7.10(bs, 1H), 6.50(d, 1H), 5.60(m, 1H),
    5.39(m, 1H), 4.90(m, 1H), 4.70(d, 1H), 4.42(t, 1H),
    4.10(m, 1H), 3.98(m, 1H), 3.17(m, 2H), 2.80(m, 1H),
    2.59(m, 1H), 2.27(m, 1H), 1.91(m, 1H), 1.83(m, 1H),
    1.68(m, 4H), 1.58(m, 1H), 1.50(m, 1H), 1.40(m, 2H),
    1.20(m, 2H), 1.10(m, 1H), 0.9-1.0(m, 21H), 0.84(d, 2H),
    0.60(m, 2H) ppm.

Claims (59)

1. A compound of formula I:
Figure US20050119189A1-20050602-C00200
or a pharmaceutically acceptable salt thereof,
wherein:
R9 and R9′ are independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to three aliphatic carbon atoms in each of R9 and R9′ may be replaced by O, N, NH, S, SO, or SO2;
wherein each of R9 and R9′ is independently and optionally substituted with up to 3 substituents independently selected from J;
J is halogen, —OR′, —NO2, —CN, —CF3, —OCF3, —R′, oxo, thioxo, ═N(R′), ═N(OR′), 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R′)2, —SR′, —SOR′, —SO2R′, —SO2N(R′)2, —SO3R′, —C(O)R′, —C(O)C(O)R′, —C(O)C(O)OR′, —C(O)C(O)N(R′)2, —C(O)CH2C(O)R′, —C(S)R′, —C(S)OR′, —C(O)OR′, —OC(O)R′, —C(O)N(R′)2, —OC(O)N(R′)2, —C(S)N(R′)2, —(CH2)0-2NHC(O)R′, —N(R′)N(R′)COR′, —N(R′)N(R′)C(O)OR′, —N(R′)N(R′)CON(R′)2, —N(R′)SO2R′, —N(R′)SO2N(R′)2, —N(R′)C(O)OR′, —N(R′)C(O)R′, —N(R′)C(S)R′, —N(R′)C(O)N(R′)2, —N(R′)C(S)N(R′)2, —N(COR′)COR′, —N(OR′)R′, —C(═NH)N(R′)2, —C(O)N(OR′)R′, —C(═NOR′)R′, —OP(O)(OR′)2, —P(O)(R′)2, —P(O)(OR′)2, or —P(O)(H)(OR′); wherein;
R′ is independently selected from:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 5 atoms in R′ are optionally and independently substituted with J;
wherein two R′ groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
R10, R10′, R11, and R11′ are each independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
wherein up to 3 aliphatic carbon atoms in each of R10, R10′, R11, and R11′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R10, R10′, R11, and R11′ is independently and optionally substituted with up to 3 substituents independently selected from J; or
R10 is —OR′ and R10′ is H; or
R10 and R10′ are both —OR′ or —SR′; or
R10 and R10′ are both fluorine; or
R10 and R10′ are taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring;
wherein the R10 and R10′ atoms bound to the carbon atom are independently C(H), N, NH, O, S, SO, or SO2;
wherein said ring may contain up to 4 heteroatoms independently selected from N, NH, O, S, SO, and SO2;
wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and
wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or
R9 and R10 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
R10 and R11 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
R9 and R11 are taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, O, S, SO, or SO2;
R1 and R3 are independently:
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-(C1-C12)aliphatic-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 3 aliphatic carbon atoms in each of R1 and R3 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R1 and R3 is independently and optionally substituted with up to 3 substituents independently selected from J;
R2, R4, and R7 are each independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or
(C6-C10)-aryl-(C1-C12)-aliphatic-;
wherein up to two aliphatic carbon atoms in each of R2, R4, and R7 may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
wherein each of R2, R4, and R7 is optionally substituted with up to 3 substituents independently selected from J;
R5 and R5′ are independently hydrogen or (C1-C12)-aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or
R5 is Ph or —CH2Ph and R5′ is H, wherein said Ph or —CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or
R5 and R5′ together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, O, SO, and SO2; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;
W is:
Figure US20050119189A1-20050602-C00201
wherein each R6 is independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-cycloalkyl- or cycloalkenyl-,
[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-,
wherein R6 is optionally substituted with up to 3 J substituents; or
two R6 groups, together with the nitrogen atom to which they are bound, optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
wherein each R8 is independently —OR′; or the R8 groups together with the boron atom, optionally form a (C3-C10)-membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR′, O, SO, and SO2;
X is —C(O)—, —S(O)—, or —S(O)2—,
V is —C(O)—, —S(O)—, —S(O)2—, or —N(R13)—;
wherein R13 is:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to two aliphatic carbon atoms in R13 may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
wherein R13 is independently and optionally substituted with up to 3 substituents independently selected from J;
R12 and R12′ are independently:
hydrogen;
(C1-C12)-aliphatic-;
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-cycloalkyl or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 3 aliphatic carbon atoms in each of R12 or R12′ may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R12 or R12′ is optionally substituted with up to 3 substituents independently selected from J; or
R12 and R12′ together with the nitrogen atom to which they are bound, form a (C3-C10)-heterocyclic ring;
wherein said (C3-C10)-heterocyclic ring is optionally substituted with up to 3 substituents independently selected from J.
2. A compound of formula I-1:
Figure US20050119189A1-20050602-C00202
or a pharmaceutically acceptable salt thereof,
wherein:
z is 0 or 1;
R9 and R9′ are independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to three aliphatic carbon atoms in each of R9 and R9′ may be replaced by O, N, NH, S, SO, or SO2;
wherein each of R9 and R9′ is independently and optionally substituted with up to 3 substituents independently selected from J;
J is halogen, —OR′, —NO2, —CN, —CF3, —OCF3, —R′, oxo, thioxo, ═N(R′), ═N(OR′), 1,2-methylenedioxy, 1,2-ethylenedioxy, —N(R′)2, —SR′, —SOR′, —SO2R′, —SO2N(R′)2, —SO3R′, —C(O)R′, —C(O)C(O)R′, —C(O)C(O)OR′, —C(O)C(O)N(R′)2, —C(O)CH2C(O)R′, —C(S)R′, —C(S)OR′, —C(O)OR′, —OC(O)R′, —C(O)N(R′)2, —OC(O)N(R′)2, —C(S)N(R′)2, —(CH2)0-2NHC(O)R′, —N(R′)N(R′)COR′, —N(R′)N(R′)C(O)OR′, —N(R′)N(R′)CON(R′)2, —N(R′)SO2R′, —N(R′)SO2N(R′)2, —N(R′)C(O)OR′, —N(R′)C(O)R′, —N(R′)C(S)R′, —N(R′)C(O)N(R′)2, —N(R′)C(S)N(R′)2, —N(COR′)COR′, —N(OR′)R′, —C(═NH)N(R′)2, —C(O)N(OR′)R′, —C(═NOR′)R′, —OP(O)(OR′)2, —P(O)(R′)2, —P(O)(OR′)2, or —P(O)(H)(OR′); wherein;
R′ is independently selected from:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 5 atoms in R′ are optionally and independently substituted with J;
wherein two R′ groups bound to the same atom optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
R10, R10′, R11, and R11′ are each independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
wherein up to 3 aliphatic carbon atoms in each of R10, R10′, R11, and R11′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R10, R10′, R11, and R11′ is independently and optionally substituted with up to 3 substituents independently selected from J; or
R10 is —OR′ and R10′ is H; or
R10 and R10′ are both —OR′ or —SR′; or
R10 and R10′ are both fluorine; or
R10 and R10′ are taken together with the carbon atom to which they are bound to form a 5- to 7-membered saturated or partially unsaturated ring;
wherein the R10 and R10′ atoms bound to the carbon atom are independently C(H), N, NH, O, S, SO, or SO2;
wherein said ring may contain up to 4 heteroatoms independently selected from N, NH, O, S, SO, and SO2;
wherein any atom is optionally singly or multiply substituted with up to 2 substituents selected independently from J; and
wherein said ring is optionally fused to a second ring selected from (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, and a (C3-C10)heterocyclyl, wherein said second ring has up to 3 substituents selected independently from J; or
R9 and R10 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
R10 and R11 are taken together with the ring atoms to which they are bound to form a 3- to 6-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, or SO2; wherein said ring is optionally substituted with up to 3 substituents selected independently from J; or
R9 and R11 are taken together with the ring atoms to which they are bound to form a bridged bicyclic saturated or partially unsaturated carbocyclic or heterocyclic ring system containing up to 10 atoms; wherein said ring system is optionally substituted with up to 3 substituents selected independently from J; wherein each heteroatom in the heterocyclic ring system is selected from the group consisting of N, NH, O, S, SO, or SO2;
R1 (if present) and R3 are independently:
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-(C1-C12)aliphatic-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 3 aliphatic carbon atoms in each of R1 (if present) and R3 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R1 (if present) and R3 is independently and optionally substituted with up to 3 substituents independently selected from J;
R2, R4, and R7 (if present) are each independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl-(C1-C12)-aliphatic-, or
(C6-C10)-aryl-(C1-C12)-aliphatic-;
wherein up to two aliphatic carbon atoms in each of R2, R4, and R7 (if present) may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
wherein each of R2, R4, and R7 (if present) is optionally substituted with up to 3 substituents independently selected from J;
R5 and R5′ are independently hydrogen or (C1-C12)-aliphatic, wherein any hydrogen is optionally replaced with halogen; wherein any terminal carbon atom of R5 is optionally substituted with sulfhydryl or hydroxy; or R5 is Ph or —CH2Ph and R5′ is H, wherein said Ph or —CH2Ph group is optionally substituted with up to 3 substituents independently selected from J; or
R5 and R5′ together with the atom to which they are bound optionally form a 3- to 6-membered saturated or partially unsaturated ring having up to 2 heteroatoms selected from N, NH, O, SO, and SO2; wherein said ring is optionally substituted with up to 2 substituents selected independently from J;
W is:
Figure US20050119189A1-20050602-C00203
wherein
Y is —CO2H, a derivative of —CO2H, or a bioisostere of —CO2H;
each R6 is independently:
hydrogen-,
(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-cycloalkyl- or cycloalkenyl-,
[(C3-C10)-cycloalkyl- or cycloalkenyl]-(C1-C12)-aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-,
wherein R6 is optionally substituted with up to 3 J substituents; or
two R6 groups, together with the nitrogen atom to which they are bound, optionally form a 3- to 10-membered aromatic or non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, S, SO, and SO2, wherein said ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or a (C3-C10)heterocyclyl, wherein any ring has up to 3 substituents selected independently from J;
wherein each R8 is independently —OR′; or the R8 groups together with the boron atom, optionally form a (C3-C10)-membered heterocyclic ring having in addition to the boron up to 3 additional heteroatoms selected from N, NR′, O, SO, and SO2;
X is —C(O)—, —S(O)—, or —S(O)2—,
V is —C(O)-*, —S(O)—, —S(O)2—, or —N(R13)—;
wherein R13 is:
hydrogen-,
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to two aliphatic carbon atoms in R13 may be replaced by a heteroatom selected from O, N, NH, S, SO, and SO2 in a chemically stable arrangement;
wherein R13 is independently and optionally substituted with up to 3 substituents independently selected from J;
R12 and R12, are independently:
hydrogen;
(C1-C12)-aliphatic-;
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-cycloalkyl or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 3 aliphatic carbon atoms in each of R12 or R12′ may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R12 or R12′ is optionally substituted with up to 3 substituents independently selected from J; or
R12 and R12′ together with the nitrogen atom to which they are bound, form a (C3-C10)-heterocyclic ring;
wherein said (C3-C10)-heterocyclic ring is optionally substituted with up to 3 substituents independently selected from J; and
R14 and R15 are independently:
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
[(C3-C10)-cycloalkyl- or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-(C1-C12)aliphatic-,
wherein up to 3 aliphatic carbon atoms in R14 and R15 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement;
wherein each of R14 and R15 is independently and optionally substituted at each substitutable position with up to 3 substituents independently selected from J.
3. The compound according to claim 1 or claim 2, wherein the
Figure US20050119189A1-20050602-C00204
radical is:
Figure US20050119189A1-20050602-C00205
wherein:
R12, R12′, and R13 are as defined in claim 1 or claim 2.
4. The compound according to claim 3, wherein the in the
Figure US20050119189A1-20050602-C00206
radical;
R12′ is hydrogen;
R12 is:
(C1-C12)-aliphatic-;
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-cycloalkyl or -cycloalkenyl-,
[(C3-C10)-cycloalkyl or -cycloalkenyl]-(C1-C12)-aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)-aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement; and
wherein R12 is optionally substituted with up to 3 substituents independently selected from J; and
R13 is as defined in claim 1 or claim 2.
5. The compound according to claim 4, wherein;
R12 is:
(C1-C12)-aliphatic-;
(C6-C10)-aryl-(C1-C12)aliphatic-, or (C3-C10)-cycloalkyl or -cycloalkenyl-;
wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement; and
wherein R12 is optionally substituted with up to 3 substituents independently selected from J; and
R13 is as defined in claim 1 or claim 2.
6. The compound according to claim 5, wherein the radical is:
Figure US20050119189A1-20050602-C00207
7. The compound according to claim 6, wherein the
Figure US20050119189A1-20050602-C00208
radical is:
Figure US20050119189A1-20050602-C00209
8. The compound according to claim 1 or claim 2, wherein the
Figure US20050119189A1-20050602-C00210
radical is:
Figure US20050119189A1-20050602-C00211
wherein:
R12, R12′, and R13 are as defined in claim 1 or claim 2.
9. The compound according to claim 8, wherein:
R12′ is hydrogen; and
R12 is:
(C1-C12)-aliphatic-;
(C6-C10)-aryl-(C1-C12)aliphatic-, or
(C3-C10)-cycloalkyl or -cycloalkenyl-;
wherein up to 3 aliphatic carbon atoms in R12 may be replaced by a heteroatom selected from O, N, NH, S, SO, or SO2 in a chemically stable arrangement; and
wherein R12 is optionally substituted with up to 3 substituents independently selected from J.
10. The compound according to any one of claims 1-9, wherein the
Figure US20050119189A1-20050602-C00212
radical is:
Figure US20050119189A1-20050602-C00213
wherein:
n is 0, 1, or 2;
Z and Z′ are independently C(H), N, NH, O, or S;
R9, R9′, R11, and R11′ are as defined in claim 1; and
the spirocyclic ring containing Z and Z′ is optionally substituted with up to 3 J substituents, wherein J is as defined in claim 1.
11. The compound according to claim 10, wherein the radical is:
Figure US20050119189A1-20050602-C00214
wherein:
R9, R9′, R11, and R11′ are H; and
n is 0, 1, or 2.
12. The compound according to claim 11, wherein the
Figure US20050119189A1-20050602-C00215
radical is:
Figure US20050119189A1-20050602-C00216
wherein:
n is 0 or 1.
13. The compound according to any one of claims 1-9, wherein the
Figure US20050119189A1-20050602-C00217
radical is:
Figure US20050119189A1-20050602-C00218
wherein:
R′ is:
(C6-C10)-aryl-,
(C6-C10)-aryl-(C1-C12)aliphatic-,
(C3-C10)-heterocyclyl-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-,
(C5-C10)-heteroaryl-, or
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 5 atoms in R′ are optionally and independently substituted with J; and
R9, R9′, R10′, R11, and R11′ are as defined in claim 1.
14. The compound according to claim 13, wherein the
Figure US20050119189A1-20050602-C00219
radical is:
Figure US20050119189A1-20050602-C00220
wherein the R′ ring is optionally substituted with up to 5 substituents independently selected from J.
15. The compound according to claim 14, wherein the radical is:
Figure US20050119189A1-20050602-C00221
16. The compound according to any one of claims 1-9, wherein the
Figure US20050119189A1-20050602-C00222
radical is:
Figure US20050119189A1-20050602-C00223
wherein:
R′ is selected from:
(C6-C10)-aryl-(C1-C12) aliphatic-,
(C3-C10)-heterocyclyl-(C1-C12)aliphatic-, and
(C5-C10)-heteroaryl-(C1-C12)-aliphatic-;
wherein up to 5 atoms in R′ are optionally and independently substituted with J; and
R9, R9′, R10′, R11, and R11′ are as defined in claim 1.
17. The compound according to claim 16, wherein the
Figure US20050119189A1-20050602-C00224
radical is:
Figure US20050119189A1-20050602-C00225
wherein up to 5 atoms in R′ are optionally and independently substituted with J.
18. The compound according to anyone of claims 1-9, wherein in the
Figure US20050119189A1-20050602-C00226
radical;
R9, R10, R10′, R11, and R11′ are as defined in claim 1; and
R9′ is:
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
(C6-C10)-aryl-,
(C3-C10)-heterocyclyl-, or
(C5-C10)-heteroaryl-;
wherein up to three aliphatic carbon atoms in R9′ may be replaced by O, N, NH, S, SO, or SO2; and
wherein R9′ is independently and optionally substituted with up to 3 substituents independently selected from J.
19. The compound according to claim 18, wherein the radical is:
Figure US20050119189A1-20050602-C00227
wherein R9′ is independently and optionally substituted with up to 3 substituents independently selected from J.
20. The compound according to any one of claims 1-9, wherein in the
Figure US20050119189A1-20050602-C00228
radical;
R9, R9′, R10, R11, and R11′ are H; and
R10′ is:
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
(C6-C10)-aryl-,
wherein any ring is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
wherein up to 3 aliphatic carbon atoms in R10′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement; and
wherein R10′, is independently and optionally substituted with up to 3 substituents independently selected from J.
21. The compound according to claim 20, wherein the radical is:
Figure US20050119189A1-20050602-C00229
wherein the R10′ group, is independently and optionally substituted with up to 3 substituents independently selected from J.
22. The compound according to any one of claims 1-9, wherein in the
Figure US20050119189A1-20050602-C00230
radical,
R9, R10, R11, and R11′ are H; and
R9′ and R10′ are:
(C1-C12)-aliphatic-,
(C3-C10)-cycloalkyl- or -cycloalkenyl-,
wherein up to 3 aliphatic carbon atoms in R9′ and R10′ may be replaced by a heteroatom selected from O, NH, S, SO, or SO2 in a chemically stable arrangement; and
wherein R9′ and R10′ are independently and optionally substituted with up to 3 substituents independently selected from J.
23. The compound according to claim 22, wherein the radical is:
Figure US20050119189A1-20050602-C00231
24. The compound according to any one of claims 1-9, wherein the
Figure US20050119189A1-20050602-C00232
radical is:
Figure US20050119189A1-20050602-C00233
wherein;
ring A is a 5- to 6-membered aromatic or a 3- to 6-membered non-aromatic ring having up to 3 heteroatoms independently selected from N, NH, O, SO, or SO2;
wherein said ring A is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
wherein any ring has up to 3 substituents selected independently from J; and
R9, R9′, R10′, and R11′ are as defined in claim 1.
25. The compound according to claim 24, wherein the radical is:
Figure US20050119189A1-20050602-C00234
wherein any ring has up to 3 substituents selected independently from J.
26. The compound according to claim 25, wherein the radical is:
Figure US20050119189A1-20050602-C00235
wherein any ring has up to 3 substituents selected independently from J.
27. The compound according to claim 26, wherein the radical is:
Figure US20050119189A1-20050602-C00236
28. The compound according to any one of claims 1-9, wherein the
Figure US20050119189A1-20050602-C00237
radical is:
Figure US20050119189A1-20050602-C00238
wherein:
ring B forms a 3- to a 20-membered carbocyclic or heterocyclic ring system;
wherein each ring B is either aromatic or nonaromatic;
wherein each heteroatom in the heterocyclic ring system is N, NH, O, SO, or SO2;
wherein ring B is optionally fused to a (C6-C10)aryl, (C5-C10)heteroaryl, (C3-C10)cycloalkyl, or (C3-C10)heterocyclyl;
wherein each ring has up to 3 substituents selected independently from J; and
R9′ and R11′ are as defined in claim 1.
29. The compound according to claim 28, wherein the
Figure US20050119189A1-20050602-C00239
radical is:
Figure US20050119189A1-20050602-C00240
30. The compound according to any one of claims 1-29, wherein W is:
Figure US20050119189A1-20050602-C00241
wherein in the W, the NR6R6 is selected from —NH—(C1-C6 aliphatic), —NH—(C3-C6 cycloalkyl), —NH—CH(CH3)-aryl, or —NH—CH(CH3)-heteroaryl, wherein said aryl or said heteroaryl is optionally substituted with up to 3 halogens.
31. The compound according to claim 30, wherein in the W, the NR6R6 is:
Figure US20050119189A1-20050602-C00242
32. The compound according to claim 31, wherein in the W, the NR6R6 is:
Figure US20050119189A1-20050602-C00243
33. The compound according to claim 32, wherein in the W, the NR6R6 is:
Figure US20050119189A1-20050602-C00244
34. The compound according to claim 33, wherein in the W, the NR6R6 is:
Figure US20050119189A1-20050602-C00245
35. The compound according to any one of claims 1-34, wherein R5′ is hydrogen and R5 is:
Figure US20050119189A1-20050602-C00246
36. The compound according to claim 35, wherein R5′ is hydrogen and R5 is:
Figure US20050119189A1-20050602-C00247
37. The compound according to any one of claims 1-36, wherein R2, R4, R7, and R12′, if present, are each independently H, methyl, ethyl, or propyl.
38. The compound according to claim 37, wherein R2, R4, R7, and R12′, if present, are each H.
39. The compound according to any one of claims 1-38, wherein R3 is:
Figure US20050119189A1-20050602-C00248
40. The compound according to claim 39, wherein R3 is:
Figure US20050119189A1-20050602-C00249
41. The compound according to claim 40, wherein R3 is:
Figure US20050119189A1-20050602-C00250
42. The compound according to any one of claims 1-41, wherein R1, if present, is:
Figure US20050119189A1-20050602-C00251
43. The compound according to claim 42, wherein R1, if present, is:
Figure US20050119189A1-20050602-C00252
44. The compound according to claim 43, wherein R1, if present, is cyclohexyl.
45. The compound according to claim 1, wherein the compound is:
Figure US20050119189A1-20050602-C00253
46. A pharmaceutical composition comprising a compound according to any one of claims 1-45, or a pharmaceutically acceptable salt thereof in an amount effective to inhibit a serine protease; and a acceptable carrier, adjuvant or vehicle.
47. The composition according to claim 46, wherein said composition is formulated for administration to a patient.
48. The composition according to claim 47, wherein said composition comprises an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; and a cytochrome P-450 inhibitor; or combinations thereof.
49. The composition according to claim 48, wherein said immunomodulatory agent is α-, β-, or γ-interferon or thymosin; said antiviral agent is ribavirin, amantadine, or telbivudine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
50. The composition according to claim 48, wherein said cytochrome P-450 inhibitor is ritonavir.
51. A method of inhibiting the activity of a serine protease comprising the step of contacting said serine protease with a compound according to any one of claims 1-45.
52. The method according to claim 51, wherein said protease is an HCV NS3 protease.
53. A method of treating an HCV infection in a patient comprising the step of administering to said patient a composition according to claim 47.
54. The method according to claim 53, comprising administering to said patient an additional agent selected from an immunomodulatory agent; an antiviral agent; a second inhibitor of HCV protease; an inhibitor of another target in the HCV life cycle; or combinations thereof; wherein said additional agent is administered to said patient as part of said composition according to claim 47 or as a separate dosage form.
55. The method according to claim 54, wherein said immunomodulatory agent is α-, β-, or γ-interferon or thymosin; said antiviral agent is ribavarin or amantadine; or said inhibitor of another target in the HCV life cycle is an inhibitor of HCV helicase, polymerase, or metalloprotease.
56. A method of eliminating or reducing HCV contamination of a biological sample or medical or laboratory equipment, comprising the step of contacting said biological sample or medical or laboratory equipment with a composition according to claim 46.
57. The method according to claim 56, wherein said sample or equipment is selected from blood, other body fluids, biological tissue, a surgical instrument, a surgical garment, a laboratory instrument, a laboratory garment, a blood or other body fluid collection apparatus; a blood or other body fluid storage material.
58. The method according to claim 57, wherein said body fluid is blood.
59. A process for preparing a compound of formula I, as defined in claim 1, or a compound of formula I-1 as defined in claim 2, comprising the step of: reacting a compound of formula VII in the presence of a compound of formula VIII to provide a compound of formula IX:
Figure US20050119189A1-20050602-C00254
wherein:
R17 is an amine protecting group, a P3-residue of an HCV protease inhibitor described herein, or a P4-P3-residue of an HCV protease inhibitor as described herein, and wherein the P3 and the P4-P3 residues are optionally substituted with an amino-terminal capping group;
R17 is a carboxy protecting group or a P1 residue of an HCV protease inhibitor described herein, wherein the P1 residue is optionally substituted with a carboxy terminal protecting group or with W; R′ is as defined in claim 1;
and X is an appropriate leaving group.
US10/943,265 2003-09-18 2004-09-17 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease Abandoned US20050119189A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/943,265 US20050119189A1 (en) 2003-09-18 2004-09-17 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US12/265,125 US8426359B2 (en) 2003-09-18 2008-11-05 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US13/851,303 US20130316945A1 (en) 2003-09-18 2013-03-27 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50440503P 2003-09-18 2003-09-18
US10/943,265 US20050119189A1 (en) 2003-09-18 2004-09-17 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/265,125 Continuation US8426359B2 (en) 2003-09-18 2008-11-05 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Publications (1)

Publication Number Publication Date
US20050119189A1 true US20050119189A1 (en) 2005-06-02

Family

ID=34375489

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/943,265 Abandoned US20050119189A1 (en) 2003-09-18 2004-09-17 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US12/265,125 Expired - Fee Related US8426359B2 (en) 2003-09-18 2008-11-05 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US13/851,303 Abandoned US20130316945A1 (en) 2003-09-18 2013-03-27 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/265,125 Expired - Fee Related US8426359B2 (en) 2003-09-18 2008-11-05 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US13/851,303 Abandoned US20130316945A1 (en) 2003-09-18 2013-03-27 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Country Status (8)

Country Link
US (3) US20050119189A1 (en)
EP (1) EP1664091A1 (en)
JP (1) JP4685775B2 (en)
AR (1) AR045769A1 (en)
AU (1) AU2004274468B2 (en)
CA (1) CA2538791A1 (en)
TW (1) TW200526686A (en)
WO (1) WO2005028502A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020197828A1 (en) * 2001-06-21 2002-12-26 Hitachi Kokusai Electric Inc. Method and apparatus for manufacturing a semiconductor device and processing a substrate
US20030236242A1 (en) * 2000-04-03 2003-12-25 Robert Perni Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US20050080017A1 (en) * 2003-10-10 2005-04-14 Cottrell Kevin M. Inhibitors of serine proteases, particularly HVC NS3-NS4A protease
US20050197299A1 (en) * 2000-08-31 2005-09-08 Babine Robert E. Peptidomimetic protease inhibitors
US20050215486A1 (en) * 2004-02-04 2005-09-29 Kevin Cottrell Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20060211629A1 (en) * 2003-07-18 2006-09-21 Britt Shawn D Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20070054842A1 (en) * 2005-07-25 2007-03-08 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis C virus replication
US20070161789A1 (en) * 2003-10-10 2007-07-12 Cottrell Kevin M Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20070179167A1 (en) * 2005-08-26 2007-08-02 Cottrell Kevin M Inhibitors of serine proteases
US20080019942A1 (en) * 2006-07-05 2008-01-24 Intermune, Inc Novel inhibitors of hepatitis c virus replication
US20080311079A1 (en) * 2003-09-05 2008-12-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US20090104001A1 (en) * 2007-10-19 2009-04-23 Kochheiser Michael A Non-dimpling fastener
US20090143312A1 (en) * 1996-10-18 2009-06-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
US20090269305A1 (en) * 2008-04-15 2009-10-29 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US20090291902A1 (en) * 2003-09-18 2009-11-26 Cottrell Kevin M Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20100221217A1 (en) * 2009-02-27 2010-09-02 Intermune, Inc. Therapeutic composition
US20100272681A1 (en) * 2007-02-27 2010-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of Serine Proteases
US7932277B2 (en) 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US20110171175A1 (en) * 2005-08-02 2011-07-14 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US8247532B2 (en) 2006-03-16 2012-08-21 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CN102718744A (en) 2005-05-13 2012-10-10 Viro化学制药公司 Compounds and methods for the treatment or prevention of flavivirus infections
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
EP2104674B8 (en) 2006-11-15 2013-10-02 Vertex Pharmaceuticals (Canada) Incorporated Thiophene analogues for the treatment or prevention of flavivirus infections
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
BRPI0817881A2 (en) 2007-10-10 2015-03-31 Novartis Ag Organic compounds and their uses
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CN102325783A (en) 2008-12-23 2012-01-18 法莫赛特股份有限公司 Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
TWI576352B (en) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
PT2477980T (en) 2009-09-15 2016-08-31 Taigen Biotechnology Co Ltd Hcv protease inhibitors
AU2010326225A1 (en) 2009-11-25 2012-06-07 Vertex Pharmaceuticals Incorporated 5-alkynyl-thiophene-2-carboxylic acid derivatives and their use for the treatment or prevention of flavivirus infections
JP2013515746A (en) 2009-12-24 2013-05-09 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド Analogs for the treatment or prevention of flavivirus infections
TW201141857A (en) 2010-03-24 2011-12-01 Vertex Pharma Analogues for the treatment or prevention of flavivirus infections
EP2550262A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
AU2011232331A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
AU2011232348A1 (en) 2010-03-24 2012-10-11 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of Flavivirus infections
SI3290428T1 (en) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
UY33310A (en) 2010-03-31 2011-10-31 Pharmasset Inc ESTEREOSELECTIVE SYNTHESIS OF ASSETS CONTAINING PHOSPHORUS
WO2011156545A1 (en) 2010-06-09 2011-12-15 Vertex Pharmaceuticals Incorporated Viral dynamic model for hcv combination therapy
EP2582717A2 (en) 2010-06-15 2013-04-24 Vertex Pharmaceuticals Incorporated Hcv ns5b polymerase mutants
WO2012006060A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
UY33473A (en) 2010-06-28 2012-01-31 Vertex Pharma COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
WO2012006070A1 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
CA2808291A1 (en) 2010-08-17 2012-02-23 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flaviviridae viral infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
HUE036588T2 (en) 2011-09-16 2018-07-30 Gilead Pharmasset Llc Methods for treating hcv
US20130123276A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
UA118256C2 (en) 2013-01-31 2018-12-26 Гіліад Фармассет Елелсі Combination formulation of two antiviral compounds
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
SG11201600919UA (en) 2013-08-27 2016-03-30 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
JP7164521B2 (en) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー carbocyclic prolinamide derivatives
PT3472149T (en) 2016-06-21 2023-11-23 Orion Opthalmology Llc Heterocyclic prolinamide derivatives
JOP20190245A1 (en) 2017-04-20 2019-10-15 Novartis Ag Sustained release delivery systems comprising traceless linkers
TW202027794A (en) 2018-10-03 2020-08-01 瑞士商諾華公司 Sustained delivery of angiopoetin-like 3 polypeptides
CN113167802A (en) 2018-12-04 2021-07-23 百时美施贵宝公司 Analytical method using in-sample calibration curves by multi-isotopologue reaction monitoring

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265380B1 (en) * 1996-10-18 2001-07-24 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US6608067B1 (en) * 1998-03-31 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3 protease
US6909000B2 (en) * 2001-07-11 2005-06-21 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
US20060211629A1 (en) * 2003-07-18 2006-09-21 Britt Shawn D Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20070179167A1 (en) * 2005-08-26 2007-08-02 Cottrell Kevin M Inhibitors of serine proteases
US7273885B2 (en) * 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20080045480A1 (en) * 2001-10-24 2008-02-21 Farmer Luc J Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
WO2000056331A1 (en) 1999-03-19 2000-09-28 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
ATE297946T1 (en) 2000-04-03 2005-07-15 Vertex Pharma INHIBITORS OF SERINE PROTEASES, SPECIFICALLY THE HEPATITIS C VIRUS NS3 PROTEASE
AR029851A1 (en) * 2000-07-21 2003-07-16 Dendreon Corp NEW PEPTIDES AS INHIBITORS OF NS3-SERINA PROTEASA DEL VIRUS DE HEPATITIS C
JP4298289B2 (en) * 2000-07-21 2009-07-15 シェーリング コーポレイション Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (en) 2000-08-31 2003-01-13 Lilly Co Eli INHIBITORS OF PROTEASA PEPTIDOMIMETICA REF. X-14912M
EP1613620A1 (en) 2003-04-11 2006-01-11 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
CN100453553C (en) * 2003-04-11 2009-01-21 沃泰克斯药物股份有限公司 Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
TW201127828A (en) 2003-09-05 2011-08-16 Vertex Pharma Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
AR045769A1 (en) 2003-09-18 2005-11-09 Vertex Pharma INHIBITORS OF SERINE PROTEASES, PARTICULARLY, THE HCV PROTEASE NS3-NS4A (VIRUS HEPATITIS C)
RU2006115558A (en) 2003-10-10 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) SERINE PROTEASES INHIBITORS, ESPECIALLY HCV NS3-NS4A PROTEASES
EP1711515A2 (en) 2004-02-04 2006-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265380B1 (en) * 1996-10-18 2001-07-24 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US6617309B2 (en) * 1996-10-18 2003-09-09 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US20040266731A1 (en) * 1996-10-18 2004-12-30 Tung Roger D. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US6608067B1 (en) * 1998-03-31 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3 protease
US20040077600A1 (en) * 1998-03-31 2004-04-22 Tung Roger D. Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US6909000B2 (en) * 2001-07-11 2005-06-21 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
US20080045480A1 (en) * 2001-10-24 2008-02-21 Farmer Luc J Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7273885B2 (en) * 2002-04-11 2007-09-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20060211629A1 (en) * 2003-07-18 2006-09-21 Britt Shawn D Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20070179167A1 (en) * 2005-08-26 2007-08-02 Cottrell Kevin M Inhibitors of serine proteases

Cited By (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314141B2 (en) 1996-10-18 2012-11-20 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US20090143312A1 (en) * 1996-10-18 2009-06-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
US7494988B2 (en) 2000-04-03 2009-02-24 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US20030236242A1 (en) * 2000-04-03 2003-12-25 Robert Perni Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease
US7820671B2 (en) 2000-08-31 2010-10-26 Vertex Pharmaceuticals Incorporated Peptidomimetic protease inhibitors
US20050197299A1 (en) * 2000-08-31 2005-09-08 Babine Robert E. Peptidomimetic protease inhibitors
US8529882B2 (en) 2000-08-31 2013-09-10 Vertex Pharmaceuticals Incorporated Peptidomimetic protease inhibitors
US20100137583A1 (en) * 2000-08-31 2010-06-03 Robert Edward Babine Peptidomimetic protease inhibitors
US8252923B2 (en) 2000-08-31 2012-08-28 Vertex Pharmaceuticals Incorporated Peptidomimetic protease inhibitors
US20020197828A1 (en) * 2001-06-21 2002-12-26 Hitachi Kokusai Electric Inc. Method and apparatus for manufacturing a semiconductor device and processing a substrate
US20060211629A1 (en) * 2003-07-18 2006-09-21 Britt Shawn D Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8691758B2 (en) 2003-07-18 2014-04-08 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7745444B2 (en) 2003-09-05 2010-06-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8217048B2 (en) 2003-09-05 2012-07-10 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20080311079A1 (en) * 2003-09-05 2008-12-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20110104115A1 (en) * 2003-09-05 2011-05-05 Vertex Pharmaceuticals Incoroprated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20090291902A1 (en) * 2003-09-18 2009-11-26 Cottrell Kevin M Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US8426359B2 (en) 2003-09-18 2013-04-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20070161789A1 (en) * 2003-10-10 2007-07-12 Cottrell Kevin M Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7365092B2 (en) 2003-10-10 2008-04-29 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8039623B2 (en) 2003-10-10 2011-10-18 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050080017A1 (en) * 2003-10-10 2005-04-14 Cottrell Kevin M. Inhibitors of serine proteases, particularly HVC NS3-NS4A protease
US20090111969A1 (en) * 2003-10-14 2009-04-30 Blatt Lawrence M Macrocyclic compounds as inhibitors of viral replication
US20090111982A1 (en) * 2003-10-14 2009-04-30 Blatt Lawrence M Macrocyclic compounds as inhibitors of viral replication
US20090105471A1 (en) * 2003-10-14 2009-04-23 Blatt Lawrence M Macrocyclic compounds as inhibitors of viral replication
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
US7683033B2 (en) 2004-02-04 2010-03-23 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8536136B2 (en) 2004-02-04 2013-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20050215486A1 (en) * 2004-02-04 2005-09-29 Kevin Cottrell Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US20100330109A1 (en) * 2004-02-04 2010-12-30 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7829665B2 (en) 2005-07-25 2010-11-09 Intermune, Inc. Macrocyclic inhibitors of hepatitis C virus replication
US20070054842A1 (en) * 2005-07-25 2007-03-08 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis C virus replication
US20090148407A1 (en) * 2005-07-25 2009-06-11 Intermune, Inc. Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
US8299021B2 (en) 2005-07-25 2012-10-30 Intermune, Inc. Macrocyclic inhibitors of hepatitis C virus replication
US20110171175A1 (en) * 2005-08-02 2011-07-14 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8871904B2 (en) 2005-08-19 2014-10-28 Vertex Pharmaceuticals Incorporated Processes and intermediates
US20070179167A1 (en) * 2005-08-26 2007-08-02 Cottrell Kevin M Inhibitors of serine proteases
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7985762B2 (en) 2005-08-26 2011-07-26 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US20110182856A1 (en) * 2005-08-26 2011-07-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8440706B2 (en) 2005-08-26 2013-05-14 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8372873B2 (en) 2005-08-26 2013-02-12 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US20110165120A1 (en) * 2005-08-26 2011-07-07 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US8119592B2 (en) 2005-10-11 2012-02-21 Intermune, Inc. Compounds and methods for inhibiting hepatitis C viral replication
US8247532B2 (en) 2006-03-16 2012-08-21 Vertex Pharmaceuticals Incorporated Deuterated hepatitis C protease inhibitors
US7781474B2 (en) 2006-07-05 2010-08-24 Intermune, Inc. Inhibitors of hepatitis C virus replication
US20080019942A1 (en) * 2006-07-05 2008-01-24 Intermune, Inc Novel inhibitors of hepatitis c virus replication
US20100209391A1 (en) * 2006-07-05 2010-08-19 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8575208B2 (en) 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US20100272681A1 (en) * 2007-02-27 2010-10-28 Vertex Pharmaceuticals Incorporated Inhibitors of Serine Proteases
US20090155209A1 (en) * 2007-05-03 2009-06-18 Blatt Lawrence M Novel macrocyclic inhibitors of hepatitis c virus replication
US7932277B2 (en) 2007-05-10 2011-04-26 Intermune, Inc. Peptide inhibitors of hepatitis C virus replication
US20090104001A1 (en) * 2007-10-19 2009-04-23 Kochheiser Michael A Non-dimpling fastener
US8048862B2 (en) 2008-04-15 2011-11-01 Intermune, Inc. Macrocyclic inhibitors of hepatitis C virus replication
US20090269305A1 (en) * 2008-04-15 2009-10-29 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US8735345B2 (en) 2009-02-27 2014-05-27 Hoffmann La Roche Inc. Therapeutic composition
US20100221217A1 (en) * 2009-02-27 2010-09-02 Intermune, Inc. Therapeutic composition
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US9394331B2 (en) 2010-11-30 2016-07-19 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections

Also Published As

Publication number Publication date
AU2004274468A1 (en) 2005-03-31
JP2007536204A (en) 2007-12-13
JP4685775B2 (en) 2011-05-18
US20090291902A1 (en) 2009-11-26
US8426359B2 (en) 2013-04-23
AU2004274468B2 (en) 2009-07-23
US20130316945A1 (en) 2013-11-28
EP1664091A1 (en) 2006-06-07
AR045769A1 (en) 2005-11-09
WO2005028502A1 (en) 2005-03-31
TW200526686A (en) 2005-08-16
CA2538791A1 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
US8426359B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8039623B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US7378422B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
US8536136B2 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4A protease

Legal Events

Date Code Title Description
AS Assignment

Owner name: VERTEX PHARMACEUTICALS INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COTTRELL, KEVIN M.;PERNI, ROBERT B.;PITLIK, JANOS;AND OTHERS;REEL/FRAME:015523/0895;SIGNING DATES FROM 20041111 TO 20041214

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION